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Abstract 
Achieving neural regeneration after spinal cord injury (SCI) represents a significant challenge. 
Neural stem cell (NSC) therapy offers replacement of damaged cells and delivery of pro-
regenerative factors, but >95% of cells die when transplanted to sites of neural injury. Biomaterial 
scaffolds provide cellular protective encapsulation to improve cell survival. However, current 
available scaffolds are overwhelmingly not approved for human use, presenting a major barrier to 
clinical translation. Surgical biomaterials offer the unique benefit of being FDA-approved for human 
implantation. Specifically, a neurosurgical grade material, DuraGenTM, used predominantly for 
human duraplasty has many attractive features of an ideal biomaterial scaffold. Here, we have 
investigated the use of DuraGenTM as a three-dimensional (3D) cell encapsulation device for 
potential use in combinatorial, regenerative therapies. To show the feasibility of enhancing the 
therapeutic potential of this construct, we genetically engineered the NSCs prior to 
DuraGenTM encapsulation, which could offer the opportunity to increase expression of therapeutic 
biomolecules at the site of injury. A combination of magnetofection and minicircle technologies 
were used for genetic engineering of the NSCs. 
I show that DuraGenTM can support the survival (ca 95% viability at 12 days) and 3D growth of NSCs. 
Key parameters including maintenance of NSC phenotype, proliferative capacity and differentiation 
into astroglial lineage cells, neurons and oligodendrocytes were unaffected by 
DuraGenTM. Furthermore, proof of concept of the capacity of DuraGenTM to maintain a viable 
genetically engineered NSC transplant population is demonstrated using reporter protein 
expression which could be detected for up to eight days (latest time point examined) within the 
construct. The findings support the concept that a ‘combinatorial therapy’, consisting of NSCs 
engineered to produce therapeutic biomolecules and protected within the DuraGenTM construct, is 
a promising clinically translatable neuro-regenerative therapy. 
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1.1 Spinal cord injury (SCI)  
1.1.1 Epidemiology of SCI 
Spinal cord injuries (SCI) have a devastating impact on the individual and their support networks. 
The global prevalence is estimated at 40-80 cases/ million/ year. The UK prevalence is estimated at 
40,000 with an incidence of 12-16 cases per million (1,2).  The incidence is increasing particularly in 
the older population and patients are increasingly likely to survive for longer with a SCI, increasing 
the number of disability adjusted life years (DALYs) incurred (3,4). SCIs most often occur in those 
aged 20-29 years. An increasing incidence peak at age 70 years and above is developing due to an 
ageing population and an increase in falls as the major SCI aetiology (5). Males are 
disproportionately affected (two: one males: females) (6).  
1.1.2 The socioeconomic consequences of SCI 
There is a significant social and economic impact of SCI globally. The unemployment rate of those 
with SCI is greater than 60%. Of children with SCI, fewer will enrol in school than the general 
population (6). Moreover, in the current NHS climate it is vital to note the cost of SCI. It is very 
difficult to assess the true cost to the NHS and to the individuals in the UK. In the USA in 1998 a 
study estimated the cost to an individual in the first year after injury would be $223,261. This cost 
would be borne by the NHS in the UK and when considered with the estimated incidence of SCI in 
the UK this suggests the annual cost of new SCI to be in the region of $175,706,407 USD (2,7). In 
addition, there are the ongoing costs of living with SCI.  This comprehensive study suggests that the 
medical costs and cost due to loss of productivity amounted to $22,573 per person per year beyond 
the first year. Again extrapolating this to the UK, this would amount to $902,920,000 USD (1,7). This 
only provides an estimation of the cost; the actual cost is likely to be more as these figures do not 
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account for home modifications, prescriptions, carers, loss of family member productivity, and the 
cost of regional SCI centres.  
1.1.3 The clinical features of SCI 
The mechanism of injury to the spinal cord varies. The most common cause, reported as 90%, is 
trauma including road traffic collisions, falls, and violence. Other causes include vascular insults 
such as arteriovenous malformations, degenerative disease including multiple sclerosis, primary 
and secondary tumour formation and disc prolapse (6). These events can result in a variety of 
injuries to the spinal cord itself, but most commonly cause a contusive lesion (8).  
Symptoms and signs vary depending on the site and extent of the injury. These can include loss of 
sensory, and/or motor function, loss of autonomic control including bladder and bowel control. In 
high cervical cord injury there is an appreciable mortality and morbidity rate, largely due to 
respiratory complications. Furthermore, many patients report chronic pain and depression. 
Moreover, many experience secondary complications of SCI including pressure ulcers, deep vein 
thromboses, and infections (6).  
Each injury will produce a different set of clinical symptoms depending on the location. The 
American Spinal Injury Association (ASIA) and the International Spinal Cord Society (ISCS) developed 
an international system which categorises the extent of SCI; this is called the ASIA Impairment Scale 
(AIS). Using both anatomical location and extent of injury they developed 5 distinct categories: A-E 
in descending order of severity. ‘A’ denotes a complete injury where no sensory or motor function 
is preserved inferior to the injured cord segment. An injury causing complete motor loss and partial 
sensory loss would be represented by a category ‘B’. ‘C and D’ represent injuries involving 
incomplete motor loss with preservation of the most caudal motor segments, including voluntary 
anal contraction. To be classified as ‘D’, the patient must display a Medical Research Council grade 
3 or above in more than half of the specified ‘key’ muscles. A category ‘E’ is given to a patient who 
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previously had deficits from a SCI but now presents with no deficit. The results of a neurological 
examination are mapped on to an ASIA chart (9). This criterion is not only useful clinically but also 
in objectively assessing outcomes in clinical trials. 
1.1.4 The pathophysiology of SCI 
At the macroscopic level, the primary injury occurs at the time of the event for instance 
compression or contusion of the cord, then following this a secondary injury occurs where there 
may be haematoma formation and oedema which can contribute to further compression.  
Following this the lesion site evolves producing a necrotic epicentre and cyst formation occurs (8). 
At the microscopic level, several processes occur in the aftermath of the injury. Firstly, astrocytes 
at the lesion site are activated and proliferate. These reactive astrocytes hypertrophy and extend 
their processes. They have been suggested to provide a protective function at this stage. The 
astrocytes ‘seal off’ the lesion and in doing so prevent the extension of inflammation and necrosis 
into the surrounding healthy cord to limit the extent of the injury (10).  
Reactive astrocytes release inflammatory cytokines which recruit microglia to the site of injury. 
Microglia act to clear debris and release pro-inflammatory cytokines which contribute to further 
tissue damage (11). The damaged neurons retract their axons away from the injury site and this is 
compounded by the demyelination of the remaining axons due to the loss of oligodendrocytes (8).  
In the chronic phase of injury, the astrocytes transform into scar-forming astrocytes and 
inflammatory cells persist and can be found at ten weeks post injury (11,12). 
The period post SCI is split into distinct time periods (figure 1.1). The initial 48 hours is classified as 
the acute phase and the subacute phase is after 48 hours up to 14 days. Towards the end of the 
subacute phase astrocytes become reactive. The period from two weeks to six months is referred 
to as the intermediate phase of injury. At around four to six months the astrocyte ‘scar’ has 
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developed. Beyond six months is categorised as a chronic injury (13). Chronology aids a comparison 
when using rodent models to investigate human diseases.  The response is well categorised in rat 
models and the astrocytes at the edge of the lesion are reactive by one to two weeks, similar to 
that in humans. However, the astrocytic ‘scar’ is established much earlier at two to three weeks 
(14).  In mice, although less well characterised, increased astrocytic staining has been observed at 
seven days post injury indicating astrocyte reactivity, with intensely reactive astrocytes by day 12 
(15). Moreover, the astrocytic scar has been detected in mice at two weeks following injury (16). 
This suggests that the pathological sequelae in rodents are similar, but shorter than that in humans. 
Figure 1.1: SCI timeline in humans adapted from (13).  
1.1.5 The barriers to regeneration in SCI 
It was previously believed that adult spinal cord neurons have no regenerative capacity. In 1928, 
Santiago Ramón y Cajal published his work describing his observations of nervous system 
regeneration including theories of neurotropism (17). This was almost forgotten until Richardson 
et al 1980 proved that spinal cord grey matter axons could cross from the cut edge of a spinal cord 
lesion to an autologous sciatic nerve graft. Richardson hypothesised that it was the central nervous 
system (CNS)  environment that prevented regeneration (18).  Peripheral nerves are capable of 
regeneration. The peripheral nervous system (PNS) environment is suggested to be promoting of 
axonal regeneration (19). The process of Wallerian degeneration, which follows PNS axotomy and 
causes fragmentation of the axon, clears the environment for axonal growth. In addition, Schwann 
cells are thought to be essential for axonal regeneration, when they are not present the axons do 
not regenerate (19,20). 
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The major component of the CNS environment thought to inhibit axonal repair is the astroglial scar. 
It is not only the physical barrier of the scar that prevents axonal regrowth, but the scar also 
produces inhibitory factors which prevent axonal regrowth. These inhibitory factors include 
extracellular matrix (ECM) components such as chondroitin and keratin sulphate proteoglycans 
which contribute to further tissue damage (21), and factors that specifically prevent neuronal 
differentiation (22) or cause the collapse of the neuronal growth cone (23) all contributing to the 
prevention of regeneration. Some vertebrates that can regenerate their spinal cords after injury, 
produce very little glial scar (24). The astrocytes at the site of SCI in urodele amphibians and teleost 
fish do not hypertrophy and do not secrete ECM components but instead play a supportive role for 
neurogenesis by providing guidance for axonal growth (25).  
The negative impact of astrocytes in mammalian SCI has been contested. Anderson et al 
demonstrated detrimental effects when the astrocytic scar does not form after SCI (26). Transgenic 
mice that did not produce activated astrocytes failed to show spontaneous axonal regrowth after 
SCI (26). Reactive astrocytes likely play a role in maintaining the blood brain barrier (BBB) 
immediately following SCI. Bush et al demonstrated that ablation of astrocytes in traumatic brain 
injury led to a failure of repair of the BBB which resulted in an influx of leukocytes and vasogenic 
oedema (27). It therefore remains unknown whether the overall impact of the astrocytic scar is 
disadvantageous or beneficial.  
The inflammatory environment immediately following SCI likely has an impact on regeneration, and 
inflammation is sustained in SCI (12). In general, inflammation is associated with a lack of 
regeneration and conversely regeneration occurs where there is a reduced inflammatory state (24). 
Microglia and macrophages play a significant role in the inflammatory state post SCI although their 
role for regeneration is complex (11). Microglia assume one of two phenotypes after CNS injury, 
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M1 polarisation or M2 polarisation. M1 microglia are cytotoxic, causing secondary damage and 
axonal retraction whereas M2 promote axonal growth (11).  
The spinal cord has also been identified as a ‘non-permissive zone’ for neuronal differentiation. 
Transplantable cells such as spinal cord stem-like cells differentiated into neurons and glia in vitro 
however when implanted into the spinal cord exclusively differentiated into glial cells. This was 
contrary to their fate in the hypothalamus where the spinal cord stem-like cells did differentiate 
into neurons (28). This suggests that the environment of the spinal cord is not permissive for 
neurogenesis (24).  
1.1.6 Current and future therapies for SCI 
A range of therapies exist for the treatment of SCI which aim to promote functional recovery, but 
none promote spinal cord regeneration. Currently, a patient experiencing a SCI may expect to 
receive a combination of anti-inflammatory drugs, immune modulators, and physical rehabilitation. 
Surgical management may be an option; this would include decompression, stabilisation, or both. 
In 2012, the Surgical Timing in Acute SCI Study (STACIS) demonstrated two grade improvements on 
the ASIA criteria after early decompressive surgery (29). 
The mainstay of treatments however, tend to focus on specific symptoms of SCI and complications 
of paralysis, particularly chronic pain management and avoidance of pressure sores (30). Other 
options include functional electrical stimulation for example peroneal nerve stimulators for 
associated foot drop, and exoskeletons to improve ambulation (31). Managing SCI patients 
urologically proves challenging due to the increased risk of urinary tract infections and calculi 
formation. Many options exist to combat this including catheterisation, urinary diversion and sacral 
root stimulation (32). In addition, psychological therapies are vital to treat the associated mental 
health problems (33).  
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Treatment with high dose methylprednisolone was shown in the National Acute SCI Studies II and 
III to improve motor and sensory function significantly (34,35) but was later discredited (36) and 
the National Institute for Health and Care Excellence (NICE) specifically state it should not  be 
administered in their guidance (37). This leaves an exciting area for development of treatments 
for SCI that can truly promote regeneration. 
The complex, multifactorial nature of the pathophysiology of SCI means that stand alone treatment 
options such as pharmaceutical interventions offer some benefit but do not improve regeneration, 
whilst treating one element of the pathology neglects another. Therefore, ‘combinatorial 
therapies’ combining multiple therapeutic interventions at the site of injury has become the 
therapeutic target. Figure 1.2 demonstrates the multiplex of treatment goals that exist in SCI and 
the different potential treatment options that could tackle them. Options include a combination of 
structural support such as biomaterials, cellular transplants, genetic modification of cells to express 
specific therapeutic molecules, systemic or local pharmaceutical delivery, epidural stimulation, 
nanotherapy or scar removal via surgery. Cell transplant, biomaterials and genetic engineering will 
be discussed in detail in later sections of this introduction. The following are examples of the variety 
of experimental treatments being investigated. 
Inflammation has been identified as a barrier to regeneration in SCI, therefore many new 
treatments are being investigated which suppress inflammation. Pharmaceuticals directed at 
specific inflammatory cytokines are being tested. Anti-tumour necrosis factor alpha (anti-TNFa) 
drugs such as Infliximab, currently used in other inflammatory mediated conditions such as 
rheumatoid arthritis, are being trialled in SCI. Treatment with infliximab after SCI in rats led to an 
increased Basso, Beattie, Bresnahan score (38).  
Remyelination of axons at an injury site is vital for regeneration. Mature functional 
oligodendrocytes are essential for myelination within the CNS. Thyroid hormone (specifically 
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triiodothyronine [T3]) has been shown to encourage NSC differentiation into oligodendrocytes and 
oligodendrocyte precursor cell (OPC) maturation into oligodendrocytes. Systemic delivery of T3 in 
rats with SCI caused hyperthyroidism, therefore a local delivery system was developed composed 
of a T3-impregnated agarose hydrogel. Implantation of this hydrogel led to an increased number of 
myelinated axons when implanted into rat SCI but did not improve locomotor scoring (39). 
To elicit function in the preserved cord distal to the lesion site, epidural stimulation is being trialled. 
The sacrolumbar regions of the cord contain internal circuits which can control the muscles they 
innervate even when the central connection is lost. A closed-circuit stimulation device is implanted 
and along with rigorous training sessions the patient was able to walk and regained some urogenital 
function. Harkema et al hypothesised that the stimulation either assisted residual descending 
pathways by summation of the signals allowing the threshold for motor neuron activation to be 
met, or that it induced axonal regeneration (40).  
A combinatorial therapy with multiple targets designed to tackle different elements of the 
pathophysiology is currently considered to be the most promising strategy to improve SCI 
regeneration. 
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Figure 1.2: The multiple therapeutic goals of SCI and some potential associated therapies. Diagram 
design adapted from (41). 
1.2 Cell transplantation can promote regeneration in SCI  
1.2.1 Cell transplantation enhances regeneration 
The CNS is not a conducive environment to growth and repair (18,42). Following an injury, the 
endogenous NSCs and progenitor cells become activated and migrate to the site of injury or 
inflammation (43–45). This is the innate CNS regeneration process, the aim being for NSCs that have 
migrated to replace lost cells and encourage regeneration. However, due to the inhibitory nature 
of the environment and often the extent of the injuries, the endogenous response is not sufficient 
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to promote repair. Therefore, significant attention in the field of regenerative medicine has been 
given to therapies that involve the delivery of neural cell transplant populations.  
When considering a cell transplant therapy, there are many features that are desirable. In general, 
for any cell transplant regardless of which system is the target the graft must achieve the desired 
benefit whilst causing minimal harmful effects. The cells should be accessible and commercial scale 
up must be possible for the population to become a realistic clinical therapy. When considering CNS 
therapy, the target is often to re-establish or improve neuronal function. This requires more 
complex cell therapy designs. Dunnett and Björklund describe the key mechanisms by which a 
neural graft can improve function in the CNS. These include full reconstruction of all the tissues at 
the site of injury or more specifically focussing on graft-host reinnervation where the therapeutic 
target is to produce functional integration of transplanted cells with host neurons. Researchers may 
also aim to provide trophic stimulation by delivering exogenous trophic factors. ‘Bystander effects’ 
are also important benefits of stem cell treatments. This occurs when the presence of the grafted 
cell exhibits beneficial effects on the host tissue by paracrine effects. It is referred to as ‘bystander’ 
because there is no long-term survival of the transplanted cells. The ‘bystander effects’ are 
commonly immunomodulatory (46,47).  
Barker outlines four essential features of a stem cell transplant population with a CNS target for 
translation to clinical trial. The first is that the stem cells must differentiate into neurons. Secondly, 
the properties of the stem cells must be reproducibly demonstrated within the laboratory. Thirdly, 
the neurons must survive long-term in vivo and produce functional benefits in animal models. 
Finally, all three of the above must occur without evidence of malignant transformation (48). 
12 
 
1.2.2 Types of neural cells for transplantation 
There are multiple neural cell populations available for transplantation, each with different 
beneficial properties. Table 1.1 outlines the pros and cons related to each of the major neural cell 
transplant populations in relation to the treatment of SCI.  
Cell transplant 
population 
Pros Cons 
Astrocytes Maintain homeostasis after CNS 
insult (49). 
Repair the BBB/ Blood-spinal barrier 
(27,50). 
Release neurotrophic factors (51–
53). 
Reduce astrocytic scar volume 
(54,55). 
Reduce secondary injury (27,56). 
Historically considered preventative 
of axonal regeneration (49). 
Release factors detrimental to axon 
growth such as chondroitin sulphate 
proteoglycans (CSPGs), reactive 
oxygen species and cytokines (57). 
Modest benefits in experimental 
trials so far (54,58,59). 
NSCs Differentiate into the three major 
cell types of the CNS (60). 
Capable of self-renewal (60). 
Produce immunomodulatory 
bystander effects (61). 
Produce neurotrophic factors (61). 
Exhibit pathotropism (43–45). 
Option for protected delivery as 
neurospheres (62). 
Can be autologously generated 
from iPSCs (63). 
Risk of teratoma formation (64,65). 
In vivo differentiation yields low 
number of neurons (66). 
Sourcing autologous cells is 
problematic for instance the process 
to derive iPSCs requires four months 
(63). 
Olfactory 
ensheathing 
cells (OECs) 
Unique neuro-regenerative 
properties throughout life (67). 
Remyelinate axons (68). 
Release neurotrophic factors (69).  
Can be obtained from olfactory 
mucosa biopsies for autologous 
transplant (70). 
Wide variation in results of 
regeneration studies (71). 
No robust benefit after 
transplantation into moderate and 
severe thoracic contusion injuries 
(72). 
Requires adjuvant therapy to 
improve efficacy (72). 
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Can be purified and grown in large 
quantities (67). 
OPCs Mature into oligodendrocytes 
which can remyelinate axons (73). 
Under specific conditions can give 
rise to astrocytes and neurons 
(74,75).  
Evidence suggests they may 
contribute to the glial scar (76). 
Increase CSPGs at the injury site (77). 
Schwann cells Remyelinate axons (78). 
Can be readily harvested from 
peripheral nerves and cultured in 
large numbers (67). 
Schwann cells will not myelinate 
axons in the presence of CNS 
astrocytes (79).  
Requires adjuvant therapy to 
improve efficacy (72). 
Table 1.1: The pros and cons of the major neural transplant populations with respect to SCI therapy. 
1.2.3 NSC transplantation for SCI 
NSCs are an ideal clinical transplant population for the treatment of SCI. They offer a multitude of 
beneficial effects for the treatment of SCI. NSCs differentiate into three cell types: astrocytes, 
neurons and oligodendrocytes. These three cell types form the basis of neural circuitry and the 
ability to transplant all three provides a unique opportunity to replace lost cells like for like (60). 
Moreover, NSCs naturally produce a variety of neurotrophic factors to encourage growth at  the 
site of injury including brain-derived neurotrophic  factor (BDNF) and neurotrophin-3 (NT3), both 
essential factors in development of the CNS (61). NSCs have been shown to decrease astrogliosis 
and they exert immunomodulatory effects on the microenvironment of SCI (61).  
There are three main ways to generate a culture of neural precursor cells or NSCs. Firstly, they can 
be derived from primary sources and cultured with growth factors to remain undifferentiated and 
continue to proliferate. In adult rodents, they can be obtained from the striatum, subependymal 
region, the dentate gyrus of the hippocampus, the thoracic spinal cord, periventricular regions and 
the olfactory bulb (80–82).  
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Secondly, neural precursor cells can be differentiated from pluripotent stem cells. Two main 
sources of neural cells in trials are embryonic stem cells and induced pluripotent stem cells (iPSCs). 
Embryonic stem cells are acquired from in vitro fertilisation clinics where the cells are donated with 
consent. This has ethical implications and the law differs internationally (80,83,84). Due to the 
controversial nature of embryonic stem cells they do not represent a popular source of NSCs. iPSCs 
on the other hand, are a favourable source of NSCs. They are induced from host tissues such as 
bone marrow and adipose tissue, so hence would be exempt from immune reaction issues. 
However, they do require a significant amount of time to be cultured and this may not always be 
possible due to ideal treatment time scales (80). 
Thirdly, neural cells can be obtained via transdifferentiation of one type of mature cell. The process 
involves inducing ‘transdifferentiation’ in a mature cell such as a fibroblast to become another type 
of mature cell such as a neural cell avoiding the pluripotent phase. For transdifferentiation to occur 
the cell population requires induction most commonly by addition of transcription factors such as 
Sox-2 (85). Transdifferentiation can also be induced via cocktails of chemical compounds (86) or via 
growth in 3D culture (87). There are multiple cell types from which this could be carried out for 
instance fibroblasts, Sertoli cells, hepatocytes and B lymphocytes. These cells could be obtained 
from the individual, transdifferentiated, and returned to the individual hence avoiding an immune 
reaction (80). 
There are two ways in which laboratories propagate NSCs. They can either be cultured as a single 
layer of cells normally on glass termed a ‘monolayer’ culture or they can be maintained as balls of 
NSCs, termed ‘neurospheres’. This is a free floating, 3D culture system where the cells are not 
adherent to a substrate. 
The concept of transplanting neural tissue was first demonstrated in Santiago Ramón y Cajal’s 
laboratory in the early 20th century, Jorge Francisco Tello, Cajal’s student, transplanted pre-
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degenerated segments of peripheral nerves onto the proximal stumps of the optic nerve. He 
observed retinal axons growing into the nerve providing the first documented proof that grafted 
neural tissue could provide the solution to neuronal injury (17). In 1975, Richard Bunge developed 
an in vitro culture of Schwann cells and hypothesised that this cell type could be transplanted to 
treat SCI (88).Then in 1980, Richardson et al demonstrated long distance axonal growth after the 
transplantation of peripheral nervous tissue (18). Continuity across the rostral and caudal stumps 
of partial SCIs in rats was demonstrated post transplantation of rat fetal spinal cord tissue by Reier 
in 1986 (89). The concept that fetal neural tissue can encourage CNS repair was further proven by 
Björklund et al in models of Parkinson’s and Huntington’s disease (90).  
The field of neural tissue engineering has evolved significantly over the last decade having now 
reached clinical trials. The following section describes some of the major pre-clinical and then 
clinical trials utilising NSCs for the treatment of SCI.  
There has been significant success with the use of NSCs from a variety of sources in animal models 
of SCI. Rodents are the most commonly used model, although primates have also been utilised. SCIs 
are induced in different ways including dropping a weight on the spine, the use of devices such as 
impactors to produce a compression injury or surgically producing a partial or complete transecting 
injury (80,91–96). Many studies have demonstrated functional and histological improvement post 
implantation of NSCs.  
One of the major outcome measures of these studies is locomotor recovery. Salazar et al injected 
human fetal derived NSCs at the SCI site 30 days after creating T9 compression injuries in mice (97).  
Mice demonstrated a significant improvement in locomotor function compared to the baseline pre-
transplant assessment. There was evidence of successful cell engraftment in both grey and white 
matter. Interestingly, NSCs differentiated predominantly into oligodendrocytes (~40%) and neurons 
(~38%) at the injury site. This differs from previous work, which suggests astrocytic differentiation 
16 
 
within the spinal cord predominated (66). In 2014, Nemati demonstrated improved locomotor 
performance and sensation in primates after transplantation of adult monkey subventricular zone 
(SVZ)-derived NSCs.  Animals were subjected to a weight drop over the spinal cord at T9-10. 
Significant and faster improvements were observed in the NSC-transplant group compared to the 
control in tail movement tests and sensation assessments (98). This demonstrates that NSC-
transplant can improve locomotor function.  
Another major outcome measure is axonal regrowth. Recently, Brock et al utilised a rat contusion 
model of SCI to investigate neural progenitor cell (NPC) transplantation. In this study, rats 
underwent a unilateral cervical (C6) contusion injury created by an impactor device. 14 days post-
injury, embryonic (E14) derived spinal cord NPCs were injected into the site. Graft axons extended 
to form synapses with host axons (bouton-like structures were observed that co-localised with a 
pre-synaptic protein, synaptophysin). The glial scar was not removed at the time of NPC 
transplantation, and these findings demonstrate that graft axons can extend into host tissue despite 
the presence of the glial scar. Additionally, rats in the NPC-graft group out-performed the control 
and fibroblast-graft groups in forelimb performance assessments (99). Kumagai et al demonstrated 
axon growth when NSCs cultured as neurospheres were implanted into contusive SCI models. They 
also described an increase in angiogenesis and remyelination in the NSC transplant group (100). 
In 2006, NSCs were used to treat two patients with SCI. Moviglia et al utilised a co-culture of 
transdifferentiated NSCs and autoimmune T-cells to promote regeneration at the site of injury. The 
delivery of the cell suspension was via selective catheterisation of feeder arteries to the lesion sites. 
This provided a more targeted delivery of cells compared to systemic intravenous delivery. Many 
safety measures were put in place. Both patients underwent an intensive neurorehabilitation 
programme post treatment. Ultimately, both patients made significant improvements in motor 
function including regaining the ability to perform some activities of daily living. Patient one 
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regained the ability to walk assisted. No adverse events were recorded. This study is very promising 
for the development of NSC therapy for SCI, however it is important to note that it is a study of two 
patients only and there was no comparison group (101).  
In another small clinical trial of just one ASIA A patient, olfactory bulb derived OECs were 
transplanted into the site of a SCI. Tabakow et al used multiple microinjections to transplant 
autologous OECs into the site of a transection injury caused by a knife. The gap between the two 
spinal cord stumps was bridged with a sural nerve graft. 11 months after the operation and 
neurorehabilitation the patient had achieved ASIA C classification. The patient had regained lower 
limb sensation and had motor improvement (102). Although the results of this trial appear highly 
promising, it must be considered that this patient had a rare transecting lesion. This may not be 
transferable to the general SCI population.  
Recently, a clinical trial involving four thoracic SCI patients was conducted to assess the safety of 
NSC transplantation. NSCs from an established cell line were injected into the site of SCI. Three out 
of the four patients showed neurological improvement at follow-up and there were no adverse 
events (103). Again, this represents a small scale clinical trial. Nonetheless, the potential success of 
utilising neural cell transplants for the treatment of SCI is evident in these studies but further 
research is required.  
1.2.4 Barriers to clinical translation of stem cell therapies  
While such data appears promising, many problems have been encountered and no single therapy 
appears to be successful. There are some general risks associated with cell transplantation. Firstly, 
the transplanted cells must provide benefit to the patient. There is a risk that the transplant 
population could fail and not provide any function. Secondly when implanting stem cells there is a 
risk of uncontrolled cellular proliferation leading to malignant transformation (104). With stem cells 
derived from an embryonic origin there is a risk of teratoma. 20% of rats injected with blastocyst 
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derived embryonic stem cells developed a teratoma in a study investigating stem cell therapy for 
Parkinson’s disease (64). Furthermore, there is evidence to suggest that NSC implantation leads to 
glioma formation; this was reported in a single case report where the patient returned four years 
after repeated intrathecal human fetal NSC treatment with evidence of a non-host glioneuronal 
neoplasm (65).  
Thirdly, whenever a therapeutic intervention includes transplantation of allogenic cells or tissue 
there is the issue of immune rejection (105,106). In organ transplantation, this is counteracted with 
the use of immunosuppressant therapy. This does not come without risk. In stem cell 
transplantation trials immunosuppression has been utilised and authors suggest that it should be 
used for a few months to a year following implantation (93,104). However, in the case of SCI the 
patient is likely to have complex health needs including an increased susceptibility to infection, 
meaning that immunosuppression may not be a favourable option.  
There are more specific challenges facing stem cell transplantation. These are poor cell survival and 
cell migration. Cell survival is a major barrier to the success of neural cell transplantation. If cell 
survival is poor, then less cells persist at the target location to provide the desired beneficial 
function. Further, if cells die during transplantation, implanting dead cells into the injury site may 
encourage an immune response. As the prolonged inflammatory response at the site of SCI is a 
barrier to regeneration, implanting dead cells could cause further damage. It is also important to 
consider that if a high proportion of cells do not survive then it would be necessary to increase the 
number of cells transplanted to maintain levels of viable cells. This poses its own issues. Cells are a 
precious commodity, particularly when derived from embryonic sources or autologously derived. 
When considering clinical translation, pharmaceutical companies will need to scale up production 
of cells to make them commercially viable. High cell death on implantation will increase expense 
and may lead to a lack of support from the pharmaceutical industry. In general <3% of cells will be 
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engrafted during transplantation (107,108) - in fact Lepore found that no transplanted fetal 
neuroepithelial stem cells survived at three days (96).  
There are many reasons for high stem cell death during transplantation. Most cells are injected into 
SCI sites via a needle. This process exerts mechanical forces on the transplant cells. The narrow 
gauge of the needle and ejection force is suggested to cause cell death and was demonstrated by 
Mahetab et al. In this study, cell viability was improved by protecting the fibroblasts in alginate 
hydrogels (109). 
Pearse et al demonstrated low viability after transplantation of OECs and Schwann cells into SCI 
sites and suggested some theories as to why the cell survival was so low (110). Firstly, allograft 
rejection could explain the high cell death. If an immune response is mounted to the implantation 
of exogenous cells it would explain why Brock et al transplanted NPCs into inbred rats to 
intentionally avoid an immune rejection (99). Secondly, Pearse suggests that inadequate 
vascularisation of the injury site could create an inhospitable environment for cell survival. Lack of 
oxygen delivery and carbon dioxide removal which increases the pH could be responsible for cell 
death. To combat this, many studies pre-expose transplant cells to hypoxia and this improves 
outcomes (111). Furthermore, the presence of cytotoxic and oxidative free radicals at the lesion 
site due to the breakdown of cellular debris could impact cell survival. Finally, when cells previously 
cultured at optimal conditions are transplanted into the lesion site they are abruptly deprived of 
serum, growth factors and structural support. This change termed ‘environmental shock’ may lead 
to the lack of cell viability seen post transplantation (110).   
For the success of the transplantation procedure, it is important that the majority of cells remain 
at the lesion site where they can differentiate and replace lost cells. In some cases, a proportion of 
the implanted NSCs will have migrated away from the site of injury (93,95). For instance, in one 
study which investigated the use of human NSCs in a mouse model of SCI, it was shown that the 
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NSCs had migrated throughout the full length of the spinal cord (97). This not only poses the issue 
that there are less cells at the site to provide the intended benefits, but there is the risk of off-target 
effects. If cells migrate to distant anatomical locations, they may act differently in the environment 
and potentially lead to malignant transformation. In addition, if cells are genetically engineered to 
produce specific biomolecules, then the secretion of those in unintended anatomical locations may 
lead to further detrimental effects. 
1.3 Encapsulation in biomaterial scaffolds offers improved cellular outcomes 
1.3.1 What are biomaterial scaffolds and why are they important?  
To address the challenges that present when utilising cellular transplants, a lot of attention has 
been focused on biomaterial scaffolds that encapsulate cells and provide a construct for their 
growth and differentiation. Figure 1.3 indicates the major benefits of biomaterial scaffolds. At the 
site of a SCI there is often a degree of cavitation; a physical structure must be used to bridge that 
gap. This also allows guidance for the immature axons to follow, encouraging the rostral and caudal 
ends of the injury site to unite (112). It is also vital that the implanted cells remain at the site of the 
injury; an encapsulating structure may maintain them in situ. 
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Figure 1.3: Benefits of a biomaterial scaffold for cellular transplant into sites of neurological injury. 
1.3.2 The ideal properties of a biomaterial for cell transplant  
There are multiple properties of biomaterials that are deemed desirable to create a cellular scaffold 
for delivery of transplant cell populations. Importantly, the material should be minimally 
immunogenic so as not to increase the inflammation at the site of SCI. It should also have 
mechanical strength but balanced against ability to conform to the site. The material would have 
to support the cells but also fit into the SCI site. The scaffold must be of such a design that nutrients 
can move freely within it to allow proliferation and maturation of the cells. Preferably, the scaffold 
would allow angiogenesis to occur within it, mimicking a natural restoration process and allowing 
delivery of nutrients, inflammatory cells, and cytokines. Moreover, the material must be 
degradable. After completing its task of transplanting the cells and supporting their initial growth it 
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must degrade to not hinder further growth. The cells must be able to either adhere to the material 
or be encapsulated within it. This would allow for safe and efficient transplantation. Additionally, 
transplantation of the material would ideally be simple, for instance an injection, to prevent inter 
operator discrepancies (113). 
 
Table 1.2: The variety of biomaterials used for stem cell transplantation studies in SCI. Adapted from 
(105). 
Origin Biomaterial 
Natural Agarose 
 Alginate 
 Chitosan 
 Collagen 
 Fibrin 
 Fibronectin 
 Gellan gum 
 Hyaluronic acid 
 Protein mixture 
Synthetic Calcium sulfate cement 
 Oligo[poly(ethylene glycol) fumarate] 
 Poly(ethylene glycol) 
 Poly-b-hydroxybutyrate 
 Poly(2-hydroxyethylmethacrylate) 
 Poly(D, L-lactic acid) 
 Poly(lactide-co-glycolide) 
 Poly(lactic-co-glycolic acid) 
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1.3.3 Current uses of biomaterials for cell transplantation  
A plethora of materials have been explored in pre-clinical research including naturally existing 
substances and synthetic ones, network structures and gels. Table 1.2 demonstrates the variety of 
biomaterials utilised in animal studies. Many materials have been patented, demonstrating the 
growing interest.  
There has been success in vitro with NSCs demonstrating cell survival, normal phenotypic 
expression and importantly differentiation into neurons in fibrin hydrogels (114), 3D gelatin-
electrospun poly (lactide-co-glycolide)/polyethylene glycol (PEG) scaffolds (115) and poly(L-lactic 
acid) nanofibers (116). Functional improvement was reported with NSCs in vivo when cultured in a 
fibrin matrix (117,118), poly lactic-co-glycolic acid (PLGA) scaffold (119,120), gelfoam scaffold (121), 
porous collagen scaffold (122) and 3D gelatin-electrospun poly (lactide-co-glycolide)/PEG scaffolds 
(115). With other cell types functional improvement is also possible, for instance a Schwann cell 
transplant in Matrigel (123) or an OEC transplant in a PLGA scaffold (124). Even acellular 
biomaterials can provide functional improvement (125). Each material has favourable qualities, but 
none has emerged optimal thus far.  
1.3.4 Problems encountered whilst utilising biomaterials for stem cell transplant 
In the process of investigating various materials for the use in CNS pathologies some major factors 
have come to light regarding the design of such materials. Firstly, the clinical safety of the material 
is paramount. The majority of the biomaterials in table 1.2 are not Food and Drug Administration 
(FDA) approved for CNS applications. When researchers wish to pursue a material to the next phase 
of clinical trial many safety aspects must be addressed. 
Many materials thus far have inhibited cell growth, and importantly neuronal growth, rather than 
promoting it. King et al investigated the use of fibronectin and fibrin as scaffolds for SCI therapy. 
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Fibronectin had few neurons growing within it at four weeks post transplantation and large cavities 
had developed between the material and the host spinal cord making it an inefficient graft material 
(126). Collagen scaffolds and gels have been found to promote glial scar formation or provide 
uneven axonal growth due to dense inclusions in the gel formulations (126). Alginate has many 
desirable properties in theory, however when used to support a variety of cells including OECs, 
Schwann cells and bone marrow derived stromal cells, it inhibited their growth and led to atypical, 
rounded phenotypes. In addition, when alginate was added to an embryonic dorsal root ganglion 
culture, neurite outgrowth was greatly reduced suggesting that this biomaterial would not support 
axon regeneration (127). Hyaluronan and methyl cellulose did not achieve a high level of cell 
survival at eight weeks post implantation (<0.05%) (108).  
The material must be degradable as mentioned above. However, it must also be able to remain 
intact until the transplanted cells are fully integrated at the host site and no longer need the 
material for support. It is suggested that in the field of orthopaedic implantations a scaffold should 
last at least two weeks (128). A CNS implant, on the other hand is likely to require a slower 
degradation rate, likely to be required up to two to four months (128). Unfortunately, hyaluronic 
acid based hydrogels for example degrade rapidly and demonstrate up to 90% degradation after 14 
days (129).  
Many materials require a complex assembly procedure with multiple components and steps that 
are often time dependent (130). Cell survival is likely to be increased with fewer steps for assembly 
and hence less disturbance to the culture. For clinical translation, products will be more appealing 
if they are simpler. This will reduce the amount of inter-operator variance and will be more 
appealing to surgeons once the product becomes commercially available.  
Finally, many studies describe significant in vitro success with the use of encapsulating biomaterials 
including improved cell survival and axonal growth. However, when tested in vivo they do not 
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provide any improvement in functional ability (108,131–133). It is vital for a successful transplant 
material that it is able to prove in vivo benefits in rodent models before moving to clinical trials. 
1.3.5 Approved surgical grade materials to act as cell encapsulation devices 
The FDA is widely considered the gold standard for the regulation of the development of medical 
drugs and devices (134). The average time for a device such as a biomaterial scaffold to go through 
FDA-approval is seven years (134). This process adds additional costs to the already mounting cost 
of developing a new medical device (135). The need for a biomaterial scaffold has been outlined 
above, however most biomaterials used in pre-clinical trials are not FDA-approved. Another group 
of biomaterials exist that are already FDA-approved and are used regularly in clinical practice (table 
1.3). These are surgical materials used for various indications including haemostasis and duraplasty. 
These pre-approved matrices could offer an existing regenerative solution for stem cell 
transplantation in SCI. The following are examples of these materials, with more specific details on 
their properties and previous experimental experience with their use.  
Biomaterial Manufacturer Clinical 
indication 
Components Evidence of 
use for cell 
encapsulation 
DuraGenTM IntegraLife 
Sciences 
Duraplasty Type 1 bovine collagen Yes 
DuraSealTM IntegraLife 
Sciences 
Dural sealant Amine solution and PEG -
based solution 
No 
TisseelTM Baxter Haemostasis Fibrin Yes 
FlosealTM Baxter Haemostasis Gelatin based Yes 
SurgicelTM Ethicon Haemostasis Oxidised regenerated 
cellulose 
Yes 
Table 1.3: Details of surgical materials that have the potential to be utilised for NSC encapsulation. 
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1.3.6 DuraGenTM (Integra LifeSciences) for duraplasty 
DuraGenTM Plus matrix is a medically approved biomaterial made from type one bovine collagen. It 
is predominantly used for duraplasty, where it allows infiltration of fibroblasts and then after six to 
eight weeks is resorbed to leave endogenous dura mater (136). Other indications include acting as 
a separation layer between the dura and overlying tissues and to prevent peridural fibrosis in 
procedures where nerve roots are exposed (137). The collagen is obtained from bovine deep flexor 
tendon; this is known to be one of the purest sources of type one collagen available. It has no 
detectable infectivity for Bovine Spongiform Encephalopathy. This specific type of collagen is also 
used for artificial skin, absorbable haemostatic sponges, and absorbable wound dressings (138). 
Integra LifeSciences boast engineered porosity to provide the optimal environment for cell 
infiltration and conformability. Moreover, research demonstrates a 0% foreign body response and 
a 1.9% infection rate (no difference compared to controls). The FDA have approved DuraGenTM for 
use as a dural substitute and have confirmed its lack of immunogenicity, cytotoxicity and 
pyrogenicity. They also verify its conformability, sterility and biocompatibility (139). 
1.3.6.1 Rationale for the use of DuraGenTM 
DuraGenTM is a popular biomaterial for use in a variety of different regenerative medicine research 
areas (table 1.4). It has been shown to provide a restorative environment in traumatic brain injury. 
Traumatic cortical brain injuries were induced in rats and following implantation of DuraGenTM the 
lesion volume, neuronal loss, and cortical dysfunction were decreased compared to the control 
(140). This suggests that DuraGenTM is the ideal material for producing a restorative environment 
for axonal regrowth. 
The properties of DuraGenTM make it an ideal material for cellular engraftment. Firstly, DuraGenTM 
is composed of collagen which has been shown to facilitate growth of CNS cells (141). It has been 
shown to support cells when acting as a dural substitute, by allowing infiltration of fibroblasts and 
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allows angiogenesis to occur within the material (142). It is highly porous which would allow 
adequate distribution of cells and removal of debris, plus circulation of medium during in vitro trials. 
Degradation time has been highlighted as a problem for scaffolds, the ideal being two to four 
months (128). DuraGenTM when utilised as a dural substitute degrades over a period of two months 
(142). Most importantly DuraGenTM has been proven safe for a CNS indication- dural graft- and is 
therefore an appealing cellular scaffold option. 
1.3.6.2 DuraGenTM for the delivery of cell transplant populations  
DuraGenTM has become a popular choice for researchers testing different cell types at different 
anatomical locations and for differing pathologies (table 1.4). Although never the direct focus of 
the studies it has played the part of guide, mould, and cell delivery mechanism. In these studies, 
they do not compare to a group where the cells are delivered without the DuraGenTM implant so 
therefore it is difficult to delineate DuraGenTM’s effect on cell survival in these studies. However, 
from their success, it would suggest that DuraGenTM is a suitable host for cellular growth. 
Orthopaedic researchers have found DuraGenTM to be especially useful for delivery of mesenchymal 
stem cells (MSC) at the site of bone defects. In a study conducted by Gafni et al, DuraGenTM was 
loaded with human bone marrow derived MSCs and implanted at the site of a rodent calvarial 
defect, which was compared to an acellular DuraGenTM control (143). MSCs were detected within 
the lesion site at eight days. After four weeks and with the addition of bone morphogenetic protein-
two delivered by the human parvovirus adeno-associated virus, they detected bone formation in 
the defect site radiographically and histologically.  Similar results were found when Steinhardt et al 
implanted human MSCs loaded at 5x106 cells/ mL in DuraGenTM into mandibular defects in mice 
after eight weeks (144). Again, the MSCs required bone morphogenetic protein- two for 
differentiation. Non-union radial fractures were tested in the same way with 2x106 genetically 
engineered MSCs/mL loaded onto the DuraGenTM. This yielded similarly promising results (145). 
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Other orthopaedic based research has found DuraGenTM to be a suitable scaffold for cellular 
growth. Kimelman-Bleich et al utilised acellular DuraGenTM at the site of a non-union radial fracture 
in rodents as a guide for host progenitor cells to infiltrate. After ten days, they described the HPCs 
as being ‘abundant’ on the DuraGenTM and subsequently with the aid of targeted gene therapy, at 
five weeks immature bone formation had occurred (146). DuraGenTM has also been used as a 
scaffold for culturing human meniscal fibrochondrocytes (147). 
Murphy et al investigated a series of orthopaedic implants for their properties when seeded with 
human MSCs, one of these was DuraGenTM. They concluded that this collagen sponge was unable 
to adequately retain cells and that hydration caused a significant decrease in pore size unable to 
sustain cell cultures (148). However, the experimental evidence shown here contradicts those 
findings and demonstrates high numbers of cells maintained within the material and able to 
regenerate tissues. 
In renal research, DuraGenTM soaked in MSCs was utilised to encapsulate the kidneys of mice. The 
mice had rhabdomyolysis-induced acute kidney injury. Biochemical markers such as creatinine and 
blood urea nitrogen were significantly reduced by the addition of MSCs in DuraGenTM. The 
intervention in question in this study was the addition of MSCs so there was no comparison of MSCs 
without the DuraGenTM. Geng et al explains why they used DuraGenTM by saying it was used to 
prevent leakage of cells and increase cellular survival for longer periods (149).  
DuraGenTM has also been used to deliver cells in human trials. A study of two cases was carried out 
by Gersey et al in which DuraGenTM implanted with autologous Schwann cells was placed at the site 
of two traumatic sciatic nerve injuries. In both cases, the patients regained motor function in the 
tibial distribution and the latter regained some sensation. In this study, DuraGenTM was used to 
transport the cells and to guide the regrowth of the sciatic nerve. Notably no tumour formation was 
recorded at 36 months follow up (150).  
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The previous studies involving DuraGenTM provided specific insights into how to utilise the 
DuraGenTM for in vitro cellular experiments. For instance, most studies that use DuraGenTM for a 
variety of cell types directly seed their cells at the desired concentration (144,145,151). However, 
Adesida et al utilised a step wise protocol to achieve cell attachment to the material. They initially 
seeded 1x106cells suspended in 10μl onto the DuraGenTM matrix, allowed a total of 45 minutes and 
at two stages added more medium to produce a total volume of 1110μl (147). 
The safety of DuraGenTM as a dural substitute has been investigated widely. However, one study 
specifically looked at DuraGenTM’s effects on neurons with the intention of establishing its safety as 
a dural substitute. To evaluate DuraGenTM’s effect on the CNS when used for duraplasty, Rabinowitz 
et al grew rat cortical neurons in DuraGenTM. When compared to the poly-L-lysine control, there 
was no difference in the viability of the neurons at three and ten days. Moreover, there was no 
difference in the length of axons or dendrites either grown on glass or DuraGenTM. DuraGenTM’s 
effect on injured neurons was also investigated, after an excitotoxic injury was induced in the 
neurons. In this experiment DuraGenTM samples were added to the monolayer culture of neurons 
to establish if its presence exacerbated the injury.  The presence of DuraGenTM did not exacerbate 
the glutamate-induced injury (152). This makes DuraGenTM a highly favourable biomaterial for use 
as a cell encapsulating device as its lack of neurotoxicity has been demonstrated. 
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Research 
area 
Study 
design 
Cell type Indication  Outcome  Ref 
Orthopaedic In vitro Human MSCs Biocompatibility 
assessment 
DuraGenTM 
unable to 
sustain cells 
(148) 
 In vivo MSCs Non-union 
fracture 
Bone formation (145) 
 In vivo 
(rodent) 
Human MSCs Calvarial defect Bone formation (143) 
 In vitro Human meniscal 
fibrochondrocytes 
(MFC) 
Meniscal 
cartilage repair 
DuraGenTM 
supported 
MFCs in culture 
(147) 
 In vivo 
(rodent) 
MSCs Mandibular 
defect 
Bone formation (144) 
 In vivo 
(rodent) 
Acellular Non-union 
fracture 
Bone formation (146) 
 In vivo 
(rodent) 
MSCs Calvarial defect Bone formation (153) 
 In vivo 
(human) 
Acellular (loaded 
with bone 
morphogenetic 
protein) 
Maxillary sinus 
floor 
augmentation 
Bone formation (154) 
 In vitro Human meniscal 
fibrochondrocytes 
(MFCs) 
Meniscal 
cartilage repair 
DuraGenTM 
supported 
MFCs in culture 
(155) 
 In vivo 
(rodent) 
MSCs Non-union 
radial bone 
defect 
Bone formation (156) 
 In vivo 
(rodent) 
MSCs Tendon repair Tendon 
regeneration 
(151) 
Renal  In vivo 
(rodent) 
MSCs Acute Kidney 
injury (AKI) 
Reduced 
biochemical 
markers of AKI 
(149) 
Neurology In vivo 
(Human) 
Autologous 
Schwann cells 
Sciatic nerve 
damage 
Improved 
motor/sensory 
function 
(150) 
 In vivo 
(rodent) 
Acellular Traumatic brain 
injury 
Reduced 
contusion 
volume, 
neuronal loss 
and cognitive 
deficit 
(140) 
 In vitro Rat cortical 
neurons 
Biocompatibility 
assessment 
Compatible 
with neuron 
growth 
(152) 
Table 1.4: DuraGenTM has been used in a multitude of in vitro and in vivo trials to support a variety 
of transplantable cell types in a range of different medical specialities.  
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To the best of our knowledge DuraGenTM has never been seeded with NSCs or been shown to allow 
their survival or differentiation.  Although evidence exists demonstrating DuraGenTM’s use in 
orthopaedic, renal, and PNS implants (table 1.4), it has never been considered as a CNS therapeutic 
option beyond its current indications.  
1.3.7 DuraSealTM (Integra LifeSciences) acts as a dural sealant 
Other surgical materials also offer potential as cell encapsulation devices. DuraSealTM is a hydrogel 
sealant used to prevent cerebrospinal fluid (CSF) leaks post operatively (157). It resembles hydrogel 
formulations used for stem cell delivery in pre-clinical trials. It is composed of a PEG ester solution 
and a trilysine amine solution which cross-link when mixed together at the point of administration 
(158). Many PEG-based hydrogels exist and have been utilised to encapsulate NSCs (159). PEG has 
been used as a therapy for SCI in pre-clinical trials; it has neuroprotective effects including repair of 
damaged cell membranes and reduction of the secondary injury (160–163).  In addition, DuraSealTM 
is compatible with the CNS with a low rate of adverse events (157).  
 DuraSealTM is absorbed after nine to 12 weeks (158), in line with the ideal time of two to four 
months for degradation (128). DuraSealTM is injected as a fluid so therefore can fill irregular cavities 
formed at the lesion site allowing it to be mouldable. It should be noted that in several case studies 
DuraSealTM expanded within the spinal column and caused spinal cord compression or cauda equina 
syndrome (164,165). To utilise an expandable material in the confined space of the spinal column 
with its hydrophilic properties may prove more damaging than beneficial. This swelling would need 
to be taken in to account when designing a therapy.  
1.3.7.1 DuraSealTM demonstrates benefits in the PNS 
Unlike DuraGenTM, no reports exist describing the use of DuraSealTM to encapsulate transplant cell 
populations. It has however, been used in a pro-regenerative capacity for peripheral nerve injury. 
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In these cases, DuraSealTM permitted the regeneration of a peripheral nerve across two cut sections. 
Lin et al repaired five-millimetre gaps in rat sciatic nerves with DuraSealTM. Within the DuraSealTM 
group restoration of motor and electrophysiological function was demonstrated and there was an 
increase in the regeneration compared to tissue glue. Regeneration was defined as achievement of 
continuity in the nerve and remyelination. Moreover, DuraSealTM did not demonstrate any 
neurotoxic effects evidenced by a decreased amount of Schwann cell apoptosis at the injury site 
compared to other groups (166). Isaacs et al also utilised DuraSealTM to repair transected sciatic 
nerves in rats. The findings  demonstrated nerve regeneration equivalent to that of the suture-only 
control, but more promisingly a decrease in scar formation (167). These findings suggest that 
DuraSealTM can facilitate regeneration and in some circumstances enhance it. From the literature, 
there is no evidence of transplant populations being grown within the gel. This may be an ideal 
injectable material for cellular transplantation.  
1.3.8 Fibrin glue for haemostasis 
There are multiple types of fibrin glue available, they are designed for assisting haemostasis in 
surgical procedures. Examples include TisseelTM (Baxter), EvicelTM (Ethicon), VitagelTM (Stryker), 
CryosealTM (Thermogenesis) and VivostatTM (Vivostat). TisseelTM for instance, much like DuraSealTM, 
begins as two separate components: fibrinogen and thrombin, which when combined mimic the 
clotting cascade to form a fibrin mesh. This fibrin mesh has been suggested to be an ideal cellular 
scaffold (168). There are multiple reports of survival of cell populations within fibrin glue. For 
instance, in cardiology research, adipose derived stem cells were combined with fibrin glue and 
injected into the left ventricular wall of rats after myocardial infarction, this produced an 
improvement in cardiac function across all parameters measured indicating muscle regeneration 
(169). MSCs were loaded in fibrin glue for the treatment of rotator cuff injuries (170). Fibrin glue 
has also supported stem cells in a rat model of cerebral ischaemia providing functional 
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improvement (171). VivostatTM, a fibrin glue made from the patient’s own blood is licenced for 
neurosurgical use and sprayed into the site (172), this could prove a non-immunogenic option. It 
has demonstrated the ability to support keratinocytes for dermal regeneration and this 
combination was sprayed onto the site (173). Spray application would be highly beneficial in the 
complex space of a SCI. Fibrin glues demonstrate the ability to encapsulate cells and transport them 
to the target so hence may be a favourable option in SCI. 
1.3.9 FlosealTM (Baxter) for haemostasis 
FlosealTM created by Baxter, is a gelatin based haemostatic agent utilised in surgical procedures. It 
has many desirable properties of a cellular scaffold. It has successfully been used to transport MSCs 
into rat sciatic nerve injuries (174). Moreover, when tested as a haemostatic agent in peripheral 
nerve repair they reported it led to a faster motor function recovery (175). This suggests that 
FlosealTM may be a supportive environment for cellular transplant and endogenous neuron growth. 
1.3.10 SurgicelTM (Ethicon) for haemostasis 
Ethicon’s SurgicelTM is also a haemostatic agent. The matrix is made from oxidised regenerated 
cellulose. This biomaterial offers the specific advantage compared to the other materials of being 
used within the brain in close association with the brain parenchyma. It is used to line cerebral 
cavities after intracerebral tumour removal. This demonstrates its robust safety when used in the 
CNS. In addition, it has previously been used for controlled drug release. In this study, SurgicelTM 
was coated with PLGA containing the drug and an evaporating solvent used to release the drug 
(176). This demonstrates its potential as a carrier substrate. Furthermore, when SurgicelTM was used 
at the site of canine iliac crest defects, as an acellular implant, radiographic and histological 
evidence of bone formation was found (177). Most importantly, SurgicelTM has been previously 
used to support MSC transplant into the site of sciatic nerve injuries. Pan et al implanted MSCs 
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within SurgicelTM into 5mm sciatic nerve defects in rats. Axon length increased in this group 
compared to the control (178). This evidence of PNS cellular implantation suggests the potential of 
SurgicelTM as a cell encapsulation device for CNS pathology. 
1.4 Genetic engineering of cell transplant populations 
1.4.1 The need for augmented cell therapies for SCI 
When considering the complex nature of the events that occur after SCI it is helpful to consider the 
process of CNS development. At this time, many processes occur simultaneously, orchestrated by 
cell signalling pathways particularly associated with the timely expression of proteins such as BDNF. 
It is suggested that recreating appropriate protein expression at the site of SCI, may encourage 
axonal growth, myelination and cellular organisation (179–187). One way to do this is to genetically 
engineer transplanted cells to express specific beneficial proteins. Genetic engineering offers the 
potential to control the complex micro-environment of SCI. This site-specific release of proteins 
avoids any undesirable systemic effects. Overexpression of proteins at the site of injury can improve 
endogenous regeneration and improve the survival of transplanted populations (188). 
1.4.2 Potential biomolecules that are beneficial for SCI regeneration 
There are multiple different proteins to choose from, each providing a distinct set of therapeutic 
targets (table 1.5). Most commonly research has focused on the increased expression of trophic 
factors, but the techniques can also be used to express enzymes that can degrade inhibitory factors 
such as CSPGs. Carwardine et al effectively engineered OECs to express chondroitinase ABC 
(ChABC), using a lentiviral vector (189).  
BDNF and NT3 are popular choices for therapeutic molecule expression for SCI. These neurotrophic 
factors promote neuronal survival and axonal regeneration. When used in combination by Zhao et 
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al, they produced synergistic effects. In this study, MSCs were transfected using lipofectamine to 
express BDNF and NT3. After transplantation into a SCI transection model, axonal sprouting was 
observed and hindlimb function improved (190). Glial cell line derived neurotrophic factor (GDNF) 
has also demonstrated benefits in animal models of SCI. This factor improves neuronal survival and 
promotes axonal regeneration similar to BDNF and NT3. It has added benefits of encouraging 
remyelination and synapse formation too. Deng et al used lentiviral vector transfection to engineer 
Schwann cells to express GDNF. When GDNF expressing Schwann cells were transplanted into a rat 
hemisection model regeneration was achieved. Parameters of regeneration included axon 
lengthening, synapse formation, new myelin production and improved hindlimb function (191).  
Stromal-derived factor 1 is a chemokine which has been used for its regeneration promoting 
properties. It provides guidance for axonal growth and due to the presence of a stromal-derived 
factor receptor on most CNS cell types, it is thought to promote cell survival. Stewart et al 
engineered MSCs to express stromal-derived factor-1, these cells were implanted into a contusion 
model of SCI. The results were promising, demonstrating decreased cavitation and an increase in 
axonal numbers (179).   
Study 
design 
Transplant 
population 
Protein 
being over-
expressed 
Therapeutic 
goal 
Gene vector Outcome Ref 
In vitro OECs BDNF Axonal growth, 
neuronal 
plasticity 
Magnetic 
nanoparticles 
(MNP) and 
minicircle 
deoxyribonuclei
c acid (DNA) 
Safe and 
efficient 
transfection 
(192) 
In vitro OECs ChABC Digestion of 
inhibitory 
CPSGs 
Lentivirus  Safe and 
efficient 
genetically 
engineered 
population  
(189) 
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In vitro  MSCs BDNF and 
GDNF 
Synaptic 
plasticity and 
repair(BDNF), 
neuronal 
survival 
promotion 
(GDNF) 
Lentivirus Safe and 
efficient 
genetically 
engineered 
population 
(193) 
In vitro Dorsal root 
ganglion 
neurons 
Silencing of 
non-muscle 
myosin II 
Axon growth 
by targeting 
growth cone 
Electroporation Axon growth (194) 
In vitro NSCs BDNF Increase in 
neuronal 
numbers and 
maturation, 
plus neuro-
protection  
MNP and 
minicircle DNA 
Safe and 
efficient 
genetically 
engineered 
population 
(195) 
In vitro Schwann 
cells 
FGF-2 Nerve 
regeneration 
across long 
gaps 
Electroporation Safe and 
efficient 
genetically 
engineered 
population 
(196) 
In vivo 
rat 
contu-
sion SCI 
model 
MSC and 
NSC 
Stromal 
derived 
factor-1 
Axonal growth Retrovirus Improved 
Basso, Beattie, 
Bresnahan 
score, tumour 
formation 
(180) 
In vivo 
rat 
contu-
sion SCI 
model 
MSC Stromal 
derived 
factor-1 
Axonal growth Retrovirus Decreased 
cavitation, 
increased 
axon numbers 
(179) 
In vivo 
rat 
comp-
lete 
transect
ion SCI 
model 
MSC NT3 or 
BDNF 
Neuronal 
survival and 
axon 
regeneration 
Lipofectamine  Axonal 
sprouting and 
improved hind 
limb function 
(190) 
In vivo 
rat tran-
section 
of 
Schwann 
cells 
NT3 Neuronal 
development, 
Lipofectamine 
or PAMAM 
dendrimer 
Axonal 
regeneration 
(182) 
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sciatic 
nerve 
survival and 
regeneration 
In vivo 
mouse 
comp-
ression 
SCI 
model 
Schwann 
cells 
Cell 
adhesion 
molecule 
L1 
Remyelination Retrovirus Faster 
locomotor 
recovery, 
axonal 
sprouting 
(183) 
In vivo 
rat 
hemi-
section 
SCI 
model 
Schwann 
cells 
GDNF Neuronal 
survival and 
axon 
regeneration 
Lentivirus Axon 
regeneration, 
synapse 
formation, 
myelin 
production, 
improved 
hindlimb 
function 
(191) 
In vivo 
rat 
hemi-
section 
SCI 
model 
NSCs NT3 Neuronal 
development, 
survival and 
regeneration 
Lentivirus Improved 
Basso, Beattie, 
Bresnahan 
score 
(184) 
In vivo 
rat 
ventral 
horn 
comp-
ression 
SCI 
model 
Fetal NPCs HB9, 
Nkx6.1, 
Neurogenin
2 
HB9 – Motor 
neuron 
specification, 
axon extension 
Nkx6.1 – 
Ventral spinal 
cord 
patterning 
Lentivirus Motor neuron 
differentiation
, axonal 
growth 
initiation 
(185) 
In vivo 
rat uni-
lateral 
tran-
section 
SCI 
model 
OECs NT3 Neuroprotecti
on and neurite 
outgrowth 
Adenovirus Tissue sparing, 
corticospinal 
tract 
sprouting, no 
functional 
change 
(186) 
In vivo 
rat 
hemi-
section 
OECs NT3 and 
BDNF 
Neuroprotecti
on and neurite 
outgrowth 
Adenovirus Decreased 
lesion volume, 
axonal 
sprouting, 
(187) 
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SCI 
model 
functional 
improvement 
Table 1.5: Successful outcomes of genetic engineering of cell transplant populations for therapeutic 
use in SCI. 
1.4.3 Barriers to clinical translation of genetically engineered cell transplant populations 
Genetic engineering offers major benefits for the treatment of SCI; however, many issues present 
themselves when considering translation to clinical practice. The issue of safety surrounding genetic 
engineering is of paramount importance. Genetic engineering poses the risk of insertional 
mutagenesis, particularly when using retroviral vectors, which can lead to oncogene expression and 
tumour formation (188,197). 
Many ethical issues surround the use of genetic engineering techniques. The long-term 
consequences of genetic engineering on individual’s health and the environment remain unknown. 
The use of viral vectors to deliver the DNA presents the risk of viral DNA changes leading to new 
strains of potentially deadly infections.  In addition, the use of bacteria to produce the DNA poses 
the risk of bacterial resistance (198).  
From a practical perspective, many factors in the research and production of genetically engineered 
therapies pose barriers to clinical translation. There are an increased number of regulatory 
challenges involved when utilising genetic engineering technologies. These can slow development 
of therapies. Abou-El-Enein et al describe the challenges to the clinical translation of their human 
immunodeficiency virus (HIV)-therapy which involves the use of genetically engineered 
haematopoietic stem cells. They discuss the prominent level of regulatory challenges and the 
expense associated. In addition, they also highlight the lack of validated safety and quality 
assessments. These factors have inhibited the advancement of this therapy to the clinic (199). 
Clinical scale-up of genetic engineering presents issues. The use of some vectors can only engineer 
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a small number of cells at a time. Advancement in the field of genetic engineering is required for 
clinical translation of such therapies. 
1.4.4 Combining genetic engineered cell transplant populations with biomaterial scaffolds 
Constructs combining genetically engineered cells and biomaterial scaffolds have been designed 
and utilised for regenerative indications before (table 1.6). Hwang et al utilised retroviral vectors 
to engineer a line of NT3-overexpressing NSCs. This cell population was loaded into poly-ɛ-
caprolactone scaffolds and implanted into rat SCIs. The use of this advanced construct increased 
behavioural scores and induced increased motor evoked potentials after transcranial stimulation 
when compared to the control, the scaffold alone and the scaffold with NSCs. Interestingly, the 
addition of ChABC increased behavioural and electrophysiological outcomes further implying that 
combinatorial therapies are the most effective for SCI (200).  
The function of NT3 can be enhanced by the additional expression of its receptor, tyrosine kinase 
neurotrophin receptor (Trk). Du et al transfected two populations of NSCs to express either NT3 or 
TrkC. When both populations were co-cultured in parallel channels of poly(lactic-co-glycolic acid) 
and transplanted into rat SCIs maximal regeneration was detected compared to one cell type in the 
scaffold or the scaffold alone. Regenerative parameters included decrease in cystic cavity size, 
increased neuronal survival, evidence of myelination and improved locomotor scores (120). Similar 
regenerative outcomes were established with NT3/Trk-expressing NSCs transplanted within a 
gelatine sponge scaffold (201). 
Deng at al used a combination of Schwann cells engineered to express GDNF encased in a poly-
acrylonitrile/ poly-vinylchloride scaffold to promote regeneration in a hemisection model of SCI. 
GDNF encouraged astrocyte migration into the graft allowing Schwann cells and astrocytes to co-
exist. The expression of GDNF improved the lesion environment for regeneration by reducing 
astrocyte reactivity and decreasing CSPG expression. This led to axonal regeneration and 
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remyelination (202). Gao et al constructed an agarose scaffold supporting BDNF-expressing MSCs. 
When transplanted into a SCI there was an increase in linear axonal growth into the lesion site. The 
study did not report functional analysis (203). The aforementioned studies corroborate that multi-
faceted combinatorial therapies for SCI are the most effective. Furthermore, it provides an evidence 
base for the concept of a biomaterial scaffold protectively encapsulating genetically engineered 
cells for therapeutic transplantation in SCI. 
Scaffold Cell 
population 
Therapeutic 
molecule 
SCI model Outcome Ref 
poly-ɛ-
caprolactone 
NSC NT3 
ChABC 
Hemisection Improved behavioural 
and 
electrophysiological 
measures 
(200) 
poly(lactic-co-
glycolic acid) 
(parallel 
channels) 
 
NSC NT3  
TrkC 
Transection Improved behavioural 
scores, electro-
physiological measures 
and neuronal survival 
with myelination 
(120) 
Gelatine sponge  NSC NT3  
TrkC 
Transection Improved behavioural 
scores, electro-
physiological measures 
and neuronal survival 
with myelination 
(201) 
Poly-acrylonitrile/ 
poly-vinylchloride 
(parallel 
channels) 
 
SC GDNF Hemisection Astrocyte migration, 
decreased reactivity 
and decreased CSPG 
expression 
(202) 
Agarose MSC BDNF Transection Axonal growth (203) 
Table 1.6: Examples of constructs combining genetically engineered cells with a biomaterial scaffold 
for SCI. Adapted from (204).  
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1.4.5 Commonly used viral vectors present disadvantages  
There are several different methods of achieving a genetically engineered population of cells (table 
1.7). The most common method is the utilisation of viral vectors. The virus integrates its DNA into 
the host’s genome which is then expressed by the host. The daughter cells of transfected cells also 
contain the integrated DNA, facilitating continued transgene expression (205). Examples of viral 
vectors include adenovirus, lentivirus and many retroviruses. Although highly efficient at 
transfecting high proportions of cells and relatively easy to use, they are immunogenic and can 
cause host cell death (206). Viral vectors have been used for their ability to produce stable gene 
expression over the life span of the cell.   However this is not always beneficial, and prolonged 
release of some factors may lead to tumourgenicity so a timed decrease in expression of product 
can be highly useful particularly in the complex SCI pathology (180). Stewart et al utilised a retroviral 
vector to engineer MSCs and NSCs to express the beneficial protein stromal derived factor-1. The 
benefits included improved locomotor scores but at the cost of tumour formation. The tumours 
were thought to be NSC in origin (180).  
1.4.6 Non-viral vector alternatives  
The newer generation of transfection vectors appear much more favourable (table 1.7). Options 
include chemical and physical methods. Chemical methods such as lipid-based transfection relies 
on the negatively charged phosphate group of DNA forming a complex with the positively charged 
lipid. The overall positive charge of the complex is attracted to the negatively charged cell 
membrane where it passes through the cell membrane. The methods by which the complex does 
this and reaches the nucleus are unknown (205). It has high success rates and is relatively 
inexpensive but can be cell-type dependent (205). Other chemical options include calcium 
phosphate, this method works on the same principles as lipid-based transfection but its efficiency 
can be  affected by the medium’s components (207). 
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Physical vectors include direct injection which is a simple principle but labour-intensive, plus 
electroporation and laser-transfection techniques which are easy but can be very costly to set up 
initially (208). The mechanism of electroporation is not known but it is thought that short electrical 
pulses disrupt the cell membranes, allowing DNA to pass through (209). Laser-transfection uses a 
laser to form a pore in the cell membrane temporarily, to allow DNA in (210). 
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Transfection techniques Pros Cons 
Viral 
Adenovirus/ lentivirus/ 
retrovirus etc 
High efficiency 
Easy to use (206) 
Difficult scale-up 
Sustained release 
(tumourgenicity) 
Immunogenic 
Cytotoxicity 
DNA cargo size limit 
Potential hazard to laboratory 
personnel (206) 
Non-viral 
Calcium phosphate High efficiency 
Low cytotoxicity (207) 
Affected by medium components 
Cell-type dependent (207) 
Direct injection Straightforward Need special instruments 
Cell death 
Labour-intensive 
Electroporation Easy to use 
No need for a vector (208) 
Expensive (208) 
Laser-irradiation Easy to use (210) Expensive (210) 
Lipid-based/ lipofection Easy to use 
No DNA cargo size limit 
High success rate 
Inexpensive 
Low cytotoxicity (205) 
Cell-type dependent (205) 
Magnetofection Easy to use 
Low cytotoxicity 
High dose-response profile 
(211) 
 
Table 1.7: The pros and cons of the major methods of transfection, split into viral and non-viral 
methods. Adapted from (205). 
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1.4.7 Magnetofection offers clinically translatable benefits as a non-viral alternative for genetic 
engineering 
Magnetofection, utilising MNPs in a magnetic field, has proven successful. Initially a complex is 
formed between the DNA and nanoparticle. This is then placed in a magnetic field with the cells 
where the complexes can be taken up by endocytosis (figure 1.4). Pickard et al demonstrated an 
efficient method of magnetofection utilising iron oxide nanoparticles that formed complexes with 
DNA plasmids which effectively transfected NSCs- known to be difficult to engineer (212).  
Magnetofection is easy to use and offers rapid transfection compared to other vectors. Moreover, 
it has an increased dose-response profile meaning that less DNA is required for high transfection 
levels (213) and large quantities of cells can be transfected at once. These factors are particularly 
important when considering clinical scale-up. For targeting specific host tissues in vivo, magnetic 
fields can be externally applied to the host tissue target to attract nanoparticle-DNA complexes 
(214).  
 
Figure 1.4: Process of magnetofection – Iron oxide nanoparticle- DNA complexes taken up into 
NSCs on an oscillating magnetic field. 
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1.4.8 DNA minicircles provide significant benefits over DNA plasmids for genetic engineering 
DNA minicircles are small circular DNA sequences that, unlike DNA plasmids, do not have a bacterial 
backbone. Minicircles contain primarily the promoter, transgene and polyadenylation signal. This 
has major advantages due to the decrease in size of the DNA. It is known that a larger DNA cargo is 
associated with a decrease in nanoparticle mediated transfection efficiency (215). Without the 
excess DNA, the immune response to the process is decreased and the gene expression is sustained 
due to decreased silencing  (216). Moreover, the bacterial backbone contains the antibiotic 
resistance gene, required for isolation of the plasmid in culture; the absence of this is very 
reassuring when considering clinical application. Minicircles are easy to produce and store, and 
require relatively small amounts of DNA for high transfection yield (217). This makes clinical scale 
up highly possible which is a problem for many transfection techniques particularly viral vectors 
(206). Fernandes and Chari utilised DNA minicircles to transfect populations of NSCs with BDNF 
successfully (195,217). 
1.4.10 A genetic engineered NSC population encapsulated in DuraGenTM 
DuraGenTM has demonstrated properties of a suitable biomaterial scaffold for the encapsulation of 
NSCs for transplantation in SCI. In line with the studies in table 1.4, DuraGenTM holds the potential 
to provide a pre-approved scaffold to support genetically engineered NSCs creating a combinatorial 
therapy offering a multitude of benefits. However, unlike the materials utilised in table 1.6, 
DuraGenTM is approved for human use and is used regularly in the CNS (137). The NSCs would 
provide cell replacement and attenuation of the growth inhibitory environment (61,128). 
Additional benefit would be provided by the therapeutic molecule or combination of molecules 
expressed by the engineered NSCs. The majority of transfection for the cell populations in table 1.5 
utilised viral vectors, this construct would use a non-viral transfection method, magnetofection, 
and minicircle technology in its production adding further clinical translation benefits. To the best 
46 
 
of our knowledge DuraGenTM has never been utilised as an encapsulation matrix for NSCs which 
have been genetically engineered utilising a non-viral transfection method. 
1.5 Conclusion 
It is clear that the next step for SCI treatment will be a regenerative therapy. There has been a wide 
variety of cell types and biomaterials used with none standing out as the ideal transplant therapy. 
Many problems have presented throughout leading to no revolutionary clinical trial outcomes. 
Surgical materials offer an exciting opportunity for the field of regenerative neuroscience. To the 
best of our knowledge, DuraGenTM has never been tested as a scaffold for NSC growth.  
Genetically engineered cell populations provide useful functions to control a complex pathological 
environment. The combination of both the structural support of the DuraGenTM matrix and a 
genetically engineered clinical transplant population of NSCs appears never to have been tested 
before. If this construct is successful, it could produce a microenvironment conducive to neural 
growth and the consequences would be far reaching for the regenerative medicine field.  
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Chapter 2: Methods 
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2.1 Materials 
Primary rodent NSC culture: All culture grade plastics were from Thermo Fisher Scientific (UK). 
Media components included Dulbecco’s Modified Eagle Medium (DMEM), Ham’s F12 Medium 
(F12), B27 Supplement, Penicillin-streptomycin solution, N2 supplement all from Thermo Fisher 
Scientific plus, heparin from Sigma Aldrich (Dorset, UK). Human recombinant Epidermal Growth 
Factor (EGF) was from R&D Systems (Minnesota, USA), Human recombinant basic Fibroblast 
Growth Factor (FGF) was from Peprotech (London, UK). Fetal bovine serum was from Biosera 
(Nuiallé, France). Other culture reagents included DNAse, accutase, trypan blue, poly-ornithine and 
laminin from Sigma Aldrich, and TrypLETM Express enzyme which was from Thermo Fisher Scientific. 
Surgical materials: DuraGenTM and DuraSealTM were from Integra LifeSciences (New Jersey, USA). 
Characterisation of NSCs in DuraGenTM: The McIlwain tissue chopper was from The Mickle 
laboratory engineering co. Ltd (Guilford, UK). Calcein was from VWR (Pennsylvania, USA), Ethidium 
homodimer-1 was from Invitrogen, Hoechst was from Thermo Fisher Scientific, UK, and Click-iT EDU 
Imaging Kit was from Invitrogen (California, USA). Bovine serum albumin (BSA) and 
paraformaldehyde (PFA) were from Thermo Fisher Scientific, normal donkey serum (NDS) was from 
Stratech Scientific (Suffolk, UK), and Triton X-100 was from Sigma Aldrich. 
Antibodies for immunocytochemistry (ICC): Primary antibodies were nestin from BD Biosciences 
(Oxford, UK), anti-sox-2 from Millipore (Massachusetts, USA), purified anti-neuron-specific class III 
beta-tubulin (TUJ1) from Biolegend (California, USA); anti-Glial Fibrillary Acidic Protein (GFAP) from 
Thermo Fisher Scientific; anti-Myelin Basic Protein (MBP) from BioRad (California, USA). 
Secondary antibodies were Fluorescein isothiocyanate (FITC)-conjugated donkey anti-mouse, -
rabbit and -rat, cyanine 3 (CY3) donkey anti-mouse, -rabbit and -rat, and AMCA donkey anti-rabbit 
which were all from Stratech Scientific. Vectashield mounting medium with 4’, 6-diamidino-2-
49 
 
phenylindole (DAPI) and Vectashield mounting medium for fluorescence were from Vector 
Laboratories Inc. (Peterborough, UK). 
Minicircle plasmids containing GFP (mcGFP) production: pMC.EF1-MCS-IRES-GFP-SV40PolyA, 
GelRed, MC-EasyTM Growth Medium and MC-EasyTM Induction Medium were from Cambridge 
Biosciences (Cambridge, UK). MC-EasyTM Minicircle DNA Production kit was from System 
Biosciences (California, USA). QIAprep miniprep kit and QIA maxiprep kit were from Qiagen 
(Manchester, UK). LB Agar and LB broth were from Thermo Fisher Scientific. Kanamycin was from 
Sigma Aldrich. EcoRI was from Promega (Wisconsin, USA). Agarose was from Appleton Woods 
(Birmingham, UK). TAE buffer was made in house by Dr Sarah Harris.  
Transfection of NSCs and development of NSC-DuraGenTM construct: NeuroMag transfection 
reagent was from Oz Biosciences (Marseilles, France). Magnefect-nano 24-magnet array system 
was from NanoTherics (Stoke-on-Trent, UK). Fisherbrand pH indicator paper sticks and TurboGFP 
Polyclonal Antibody were from Thermo Fisher Scientific. 
2.2 Primary rodent NSC culture 
All experiments were conducted in accordance with the Animals (Scientific Procedures) Act of 1986 
and approved by the local ethics committee. 
2.2.1 NSC culture  
NSCs were derived and maintained as previously described (212). For this, eight to ten CD1 mouse 
pups per litter at postnatal day one to three were anaesthetised with 0.04 mL pentabarbitone via 
intraperitoneal injection. Each brain was dissected by sagittal cuts in the skin and skull, and then 
placed in PBS on ice. The SVZ of each brain was then dissected under microscopic guidance to 
identify the structures (figure 2.1). The SVZs were then dissociated using DNAse, centrifuged and 
resuspended in neurosphere medium composed of DMEM: Ham’s F12 (3:1), 4 ng/mL Heparin, 2% 
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B27, 20 ng/mL Epidermal Growth Factor (EGF), 20 ng/mL basic Fibroblast Growth Factor (FGF), 50 
U/mL penicillin and 50 U/mL streptomycin at 37⁰C. After being passed through a 40 µm cell sieve 
the cell density was calculated using a haemocytometer, and then plated at a density of 1x105 
cells/mL into T25 flasks containing 5 mL of neurosphere medium. Cultures were maintained at 37°C 
in 5% CO2/ 95% humidified air. The culture was then passaged after the cells reached confluence 
(six to ten days) and used up to passage three. Every two to three days 50% of the medium was 
replaced with fresh neurosphere medium. To prevent the cells adhering to the surface of the flask, 
a sharp tapping force was applied each day.  
 
Figure 2.1: Schematic representation of the process of producing a primary culture of NSCs. 
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2.2.2 Subculture of NSCs 
The culture was passaged when it reached confluence between six and ten days. Neurospheres 
were pooled into a 50 mL Falcon tube and centrifuged (all centrifugation steps were performed at 
1000 revolutions per minute (rpm) for five minutes). The cell pellet was then washed using 
phosphate buffered saline (PBS) and centrifuged again before addition of accutase and DNAse at a 
ratio of 9:1 and incubation at 37⁰C for five to ten minutes. Dissociation was confirmed under the 
microscope and media added to inactivate the accutase and DNAse. The suspension was 
centrifuged once more, resuspended in media and passed through a 40μm cell strainer producing 
the final cell suspension. Cells were plated into T25 flasks at a density of 0.2x105 cells/mL. 
Occasionally, the cells adhered to the surface of the flask. Therefore prior to passage, the cells 
required trypsinisation to detach them from the surface. Firstly, the medium was collected into a 
fresh tube. 5 mL Tryple was added to each flask and observed under the microscope after 20 
seconds, more time was allowed if not visibly detaching. Detached cells were then added to the 
tube of medium and passage completed as described above. 
2.2.3 Monolayer NSC culture set up 
NSCs can be cultured as neurospheres as described above or as single cell layers known as 
monolayers. To achieve a monolayer culture, coverslips first had to be prepared for NSC growth. 
For this, coverslips were shaken overnight with 1% nitric acid on an orbital shaker. Following this, 
the coverslips were shaken in deionised water for 60 minutes with water changes every ten 
minutes. Coverslips were then shaken three times in 70% ethanol for ten minutes each and then 
sonicated in 70% then 95% ethanol for 15 minutes each. Washed coverslips could then be stored in 
70% ethanol until use. For coating, each coverslip was placed in a well of a 24-well plate and washed 
with 70% ethanol for ten minutes. A 20% poly-Ornithine in deionised water solution was incubated 
on the coverslips for one hour. After aspiration of the solution, a 0.5% laminin in deionised water 
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solution was incubated on the coverslips for a further hour. Coverslips were then washed three 
times with deionised water before use.  
Dissociated NSCs were then seeded onto coverslips at a density of 1.5x105 cells/ mL in 600μl per 
well. Cells were grown in monolayer media composed of 1:1 DMEM: F12, N2 supplement, 40 μg/mL 
EGF, 40 Μg/mL basic FGF, 5 μg/mL heparin, 50 U/mL penicillin and 50 U/mL streptomycin at 37⁰C. 
50% of monolayer media was replaced every two to three days and to differentiate NSCs all 
monolayer media was removed and replaced with differentiation media. Differentiation medium 
was composed of DMEM: F12 (3:1), 2% B27 Supplement, 40 ng/mL Heparin, 50 U/mL Penicillin, 50 
U/mL Streptomycin and 1% fetal bovine serum. 
2.3 Initial trial studies of surgical materials 
2.3.1 Investigation of the porosity of surgical materials 
(1) DuraSealTM: To test the ability of DuraSealTM to allow permeation of medium, a pilot test was 
carried out utilising food colouring dye. The product DuraSealTM came as two components which 
required mixing together within the device before use. For the pilot experiment, the two 
components were injected into a bijou tube utilising the syringe like device. Food colouring dye was 
then added to the tube and observed over the next 24 hours.  
(2) DuraGenTM: To test the ability of DuraGenTM to allow permeation of medium, DMEM was added 
to a cut sample and observed. The DuraGenTM product was supplied as a dry square piece of 
material. Using a sterile scalpel, a 5mm by 5mm piece was cut. Within a petri dish, DMEM was 
added in a dropwise fashion. The material was then observed immediately under light microscopy.  
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2.3.2 Trial seeding of NSCs into DuraGenTM 
NSCs were seeded into samples of DuraGenTM under sterile conditions. Observations were made 
under a Zeiss light microscope immediately. Later, the pilot samples of DuraGenTM were 
investigated using the following initial assays: live-dead at 24 hours, nestin staining at 48 hours, 
differentiation profile at eight days (details given for each in section 1.4). 
2.3.3 Scanning electron microscopy (SEM) of DuraGenTM and DuraSealTM to assess pore size 
SEM samples were prepared in the Keele EM Unit.  Samples of each material were prepared using 
the osmium tetroxide (OsO4) and thiocarbohydrazide multiple step protocol known as OTOTO. 
OTOTO is carried out as follows. Samples of each material were provided in their original state and 
in PBS. The dry DuraGenTM sample did not survive SEM processing. Samples were first fixed in 2.5% 
glutaraldehyde diluted in 0.1M Sodium Cacodylate buffer with 2mM calcium chloride for two hours. 
All washes were carried out in Sodium Cacodylate buffer. After the first wash, samples were 
incubated with 1% OsO4 for one hour then washed again. A series of four incubations followed this: 
(1) thiocarbohydrazide for 20 minutes then (2) OsO4 for two hours, (3) thiocarbohydrazide for 20 
minutes, and (4) OsO4 for two hours. Samples were then dehydrated in a series of ethanol solutions 
of increasing concentration. Critical point drying was carried out using liquid carbon dioxide. 
Samples were then mounted on aluminium stubs in preparation for SEM. SEM was carried out at 
the standard setting of 5Kv. Images were taken at x100, x1000 and x10,000 magnification. 
For quantification of the pore size in DuraGenTM, five fields were selected: four corners and one 
central field from the x100 image. Using ImageJ (free software found at www.imagej.net), the 
largest diameter from each pore was measured. The mean and standard deviations were calculated 
to provide an estimate of the average pore size and variance in pore size. 
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2.4 Optimisation to establish methods for characterising NSC growth in 
DuraGenTM 
Prior to these investigations the methods for utilising DuraGenTM had not been systematically 
established. Studies investigating MSCs transplanted in DuraGenTM had utilised differing conditions 
including a variety of cell seeding densities (see section 1.3.6). This necessitated a structured 
approach to establishing the optimal parameters for NSC growth in DuraGenTM including developing 
appropriate ICC and microscopy protocols. The flowchart below demonstrates the steps taken to 
determine the methods used for the main body of chapter three (figure 2.2). 
 
Figure 2.2: Flowchart demonstrates the various stages of optimisation to produce a NSC-DuraGenTM 
construct.  
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2.4.1 Finding the optimal storage conditions for DuraGenTM 
A standard DuraGenTM prototype with intact packaging was received by the laboratory. To ensure 
sterility once opened it was treated with ultraviolet light. Furthermore, once a small section had 
been removed for processing the remainder was stored in its original packaging. This packaging 
came as two plastic layers. After each use, both layers would be sealed to ensure sterility of the 
sample. After processing of the DuraGenTM matrix it would most often be used immediately. In the 
event that it needed to be stored beyond this point, it was kept in medium at 4°C. Both dry storage 
and storage in medium was trialled. 
2.4.2 Optimisation of DuraGenTM thickness 
A McIlwain Tissue Chopper was used to slice equal thickness pieces of DuraGenTM under sterile 
conditions. DuraGenTM was first sliced using a scalpel and stainless-steel ruler to produce a uniform 
piece at 5mm width (figure 2.3a). A pilot study utilising these 5mm by 5mm by the pre-determined 
depth of the material was carried out. Parallel experiments were being carried out within the 
laboratory investigating other cell types. A pure astrocyte culture courtesy of Farhana Chowdhury 
was seeded into full thickness DuraGenTM sample. 
The McIlwain tissue chopper is used regularly by members of the Chari tissue engineering group for 
producing organotypic slice culture (15). An adapted protocol for DuraGenTM was trialled. Firstly, 
dry 5mm by 5mm pieces were placed on the chopping table and the chopper was set to 500µm. 
The piece could not be secured on the chopping table and was not immobilised for slicing 
accurately. Next, the piece was secured using tape or a sterile plaster to allow slicing. The 
tape/plaster was sliced with the DuraGenTM sample, potentially leading to contamination and 
making it unsuitable for culture. Finally, a drop of sterile medium was added to the DuraGenTM 
sample once on the chopping table (figure 2.3b) stabilising it for the slicing process. This method 
produced a sequence of uniformly thick slices on the chopping table by visual inspection (figure 
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2.3c). For ease of access to the slices and for storage, they were then washed using medium into a 
small petri dish where they separated. The medium used was always that which the cells would be 
later seeded in to maintain consistency. To decide the optimum thickness of DuraGenTM for culture 
three sizes were investigated: 500, 250 and 100µm. The tissue chopper was set to each thickness 
in turn producing three sets of uniformly sized slices for cell seeding. Later, 250 microns was agreed 
upon to be the most appropriate thickness (see section 3.3.3.1) and all quantitative assays were 
carried out on slices of 250µm thickness.  
 
Figure 2.3: Thickness optimisation of DuraGenTM (a) 5mm uniform DuraGenTM pieces cut with a 
scalpel with ruler for guidance (b) McIlwain tissue chopper set to 250µm ready to slice 5mm 
sample of DuraGenTM lined up on chopping table and dampened with neurosphere medium. (c) 
Chopping disc after slicing demonstrating 250µm slices of DuraGenTM ready to be washed into a 
petri dish. 
(a) (b) 
(c) 
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2.4.3 Optimisation of seeding density of DuraGenTM 
Two densities were tested: 5x105 cells/mL and 1x106 cells/mL. Densities for investigation were 
selected based on the most common cell densities used in studies investigating DuraGenTM as a cell 
encapsulation device (see section 1.3.6). Cells were counted using a haemocytometer after passage 
and then suspensions were made up to the given densities. These were then seeded on to separate 
sets of DuraGenTM. A cell viability assay, proliferation assay and ICC for NSC, astrocyte, neuron and 
oligodendrocyte markers were carried out to assess for any differences between cell densities (for 
details of these assays see section 2.5.4-7).  
2.4.4 ICC optimisation for cells in DuraGenTM 
Initially ICC was carried out following the standard protocols for monolayer cultures on coated 
coverslips. Incubation times were increased to optimise penetration of the collagen scaffold and 
numbers of washes were increased to prevent scaffold staining. For details of final optimised 
incubation times and washes see section 2.5.4-7. 
Initially, each DuraGenTM construct was mounted in Vectashield mounting medium with DAPI. It 
was discovered that Vectashield with DAPI caused staining of the DuraGenTM fibres; therefore, all 
subsequent constructs for quantification purposes were incubated with Hoechst (see section 2.5.7 
for details). Initially, the incubation time was for 15 minutes but this was not sufficient for complete 
penetration of the collagen matrix, therefore the incubation time was increased to one hour.  
2.4.5 Optimisation of imaging through DuraGenTM 
Both two-dimensional and three-dimensional imaging techniques were deployed on DuraGenTM 
samples treated with ICC. A Zeiss Axioscope A1 microscope in combination with an AxioCam ICc1 
digital camera with Axiovision software (Carl Zeiss MicroImaging GmbH, Göttingen, Germany) was 
utilised to image DuraGenTM samples in two dimensions (2D), taking different channel images and 
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then later merging relevant channels. A Zeiss Axio Observer.Z1 in combination with an AxioCam 
MRm with Zen 2.0 (blue edition) software (Carl Zeiss MicroImaging GmbH, Göttingen, Germany) 
was used to take stacks of images at varying distance intervals for 3D images. These could be 
converted to a video or a set of individual images at a later stage utilising Zen 2.0 software. 
Constructs were observed and imaged using epifluorescence microscopy whilst immersed in PBS in 
a 24-well plate. This was problematic as it moved during 3D imaging. Withdrawing a small volume 
of liquid helped but the construct was large and required a high number of slices to image the full 
thickness. In addition, the construct displayed hazy staining, possibly due to high diffraction of light 
through the large constructs, which was difficult to quantify. Subsequently, each construct was 
mounted on a microscope slide in Vectashield mounting medium (without DAPI) and covered with 
a coverslip. This allowed for stability when 3D imaging and improved image quality throughout the 
DuraGenTM samples. 
2.4.6 Finding the optimal method for triple staining of three daughter cell types in DuraGenTM 
To visualise all three cell types growing in DuraGenTM after differentiation, triple staining protocols 
were applied. Due to the risk of non-specific staining when multiple antibody protocols are used, 
two different methods were trialled. These methods were named for the purpose of this thesis the 
‘combined approach’ and the ‘sequential approach’. Primary antibodies utilised were as follows 
anti-GFAP donkey anti-rabbit, anti-TUJ1 donkey anti-mouse and anti-MBP donkey anti-rat for 
astroglial lineage cells, neurons and oligodendrocytes respectively. Secondary antibodies used were 
AMCA donkey anti-rabbit (astroglial lineage cells), FITC donkey anti-mouse (neurons) and CY3 
donkey anti-rat (oligodendrocytes). 
All DuraGenTM samples were fixed in 4% PFA in PBS following the method described in section 2.5.6. 
A 5% NDS-0.3% Triton-X100-PBS blocker was added to each sample for 30 minutes.  
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(1) Combined approach: Here, all three primary antibodies detailed above were diluted in 200µl of 
blocker per well and added to the sample. This was then incubated overnight at 4°C. The following 
day the samples were washed three times for five minutes each in PBS. A further 30 minutes of 
blocker was applied at room temperature. Next all three secondary antibodies as detailed above 
were diluted in 200µl of blocker per well and incubated for up to three hours at room temperature. 
Samples were washed three times for five minutes each in PBS.  
(2) Sequential approach: This involved the same primary and secondary antibodies as detailed 
above. The first primary antibody anti-TUJ1 was incubated overnight. The following day this was 
removed and washed as before. These samples were then blocked for 30 minutes and then the 
secondary antibody associated with anti-TUJ1, FITC donkey anti-mouse was incubated with the 
sample for up to three hours. This was then removed, washed and blocked for 30 minutes again. 
The process was repeated twice for each of the remaining antibodies. After four days the sample 
was then ready for mounting and imaging. Both approaches produced sufficiently specific staining, 
so the combined approach was utilised for all other triple cell type staining.  
These optimisation studies allowed us to determine the optimum methods for growth and 
characterisation of NSCs in DuraGenTM. Once the pilot studies were completed, a full 
characterisation of NSC growth, proliferation and differentiation was carried out.   
2.5 Characterisation of NSC growth and differentiation in DuraGenTM  
2.5.1 Seeding NSCs on to DuraGenTM 
Each slice of DuraGenTM was placed into the bottom of a well in a 24-well plate, with one sample 
per well. Each DuraGenTM sample often adhered to forceps used for transferring it into the well 
plate. To aid in releasing the sample into the well plate, a small drop of medium was required in the 
base of the plate, when the DuraGenTM touched the medium it separated from the forceps.  A 200μl 
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cell suspension was applied to the surface of the DuraGenTM dropwise to allow time for absorption 
of the cell suspension. Once the DuraGenTM sample was fully saturated by the cell suspension, the 
remainder was introduced into the surrounding area within the well. Each well was fed every other 
day by replacing 100μl of medium with 100μl of fresh neurosphere medium. 
2.5.2 Differentiation of NSCs in DuraGenTM 
To allow the stem cells to differentiate into their three main cell types – astrocytes, neurons and 
oligodendrocytes, the medium was changed 48 hours post passage. All medium from each well was 
removed then 200µl of differentiation medium was added. Each 250μm DuraGenTM slice was free-
floating within the well. Whenever medium was replaced or the scaffold was washed with PBS 
caution was taken to avoid drawing up the 3D construct with the pipette. To prevent drawing up 
the sample, the pipette tip was placed at the side of each well, away from the scaffold, and medium 
was removed gently whilst visually monitoring the slice.    
2.5.3 Assay time points 
To ensure the material had no adverse effects on the properties of NSCs the following parameters 
were measured: cell viability, cell proliferation, NSC marker expression and NSC differentiation on 
the DuraGenTM at various time points (table 2.1). Details of each assay are given below. 
 
 
 
 
 
 
61 
 
INVESTIGATION ASSAY MECHANISM TIME POINT 
CELL VIABILITY 
 
Calcein/ 
ethidium 
homodimer-1 
Calcein crosses intact cell membranes 
(live cells) and ethidium homodimer-1 
crosses disrupted cell membranes 
(dead cells) 
24 hours 
8 days 
12 days 
CELL 
PROLIFERATION 
 
EdU EdU is modified thymidine which is 
incorporated into new DNA 
(proliferating cells) 
24 hours  
8 days 
NSC MARKER 
 
Nestin 
Sox-2 
NSC cytoskeleton protein 
NSC transcription factor 
48 hours 
CELL 
DIFFERENTIATION 
 
GFAP Astrocyte cytoskeleton protein 
8 days 
12 days 
16 days 
TUJ1 Neuronal microtubule protein 
MBP Major constituent of myelin – 
produced by oligodendrocytes  
Table 2.1: Demonstrating each experimental goal, the assay used to address it and time points used. 
2.5.4 Cell viability assessment of cells in DuraGenTM 
Cell culture medium was removed from wells, and the DuraGenTM washed with PBS once. A 2 mL 
solution of PBS containing 4 μM calcein, 6 μM ethidium homodimer-1, and 2 µg/mL Hoechst was 
added to each well and incubated at 37⁰C in 5% CO2/ 95% humidified air for one hour to allow the 
solution to penetrate the matrix. The samples were fixed, mounted and then imaged. Three washes 
with PBS were added prior to fixing to ensure full removal of residual reagents. 
2.5.5 EdU Proliferation assay of cells in DuraGenTM 
For assessment of proliferation of NSCs in DuraGenTM a Click-iT EdU imaging kit was used according 
to the manufacturer’s instructions except where incubation times and washes were increased as 
follows.  Component A was incubated for 16 hours with NSCs or differentiated cells in DuraGenTM. 
Constructs were then fixed with 4% PFA for 30 minutes. Samples were washed four times with 3% 
bovine serum albumin (BSA) in PBS. 0.5% triton X-100 was added to each well for 40 minutes to 
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allow permeabilization of the cell membranes. Once again, the construct was washed four times 
with BSA. The EdU detection cocktail was prepared in accordance with the Invitrogen guidelines 
and incubated with the sample for one hour, protected from light. Constructs were washed in BSA 
twice and then PBS twice before the ICC protocol was carried out to identify nuclei and either nestin 
positive cells at 24 hours or GFAP positive cells at eight days (the two proliferating cell types, see 
section 2.5.7 for the full ICC protocol). 
2.5.6 Fixation of cells in DuraGenTM 
Unless otherwise stated, all fixation was carried out using these conditions. Firstly, medium was 
removed from the wells, and then washed with PBS. 4% PFA was added for 20 minutes. Then the 
well was rinsed with PBS three times for five minutes each. 
2.5.7 ICC of cells in DuraGenTM 
Each well was blocked for 30 minutes with a solution of 5% NDS in PBS-0.3% Triton X-100. Details 
of antibodies used are in table 2.2. Primary antibody diluted in blocker solution at the concentration 
given in the table, was added and incubated overnight. Following this, the primary antibody was 
removed and the construct was washed with PBS three times for five minutes each. Again, the 
sample was blocked for a further 30 minutes with the same blocker. Then secondary antibody 
diluted in blocker was added for up to three hours, to allow penetration of the DuraGenTM. 
Secondary antibody was matched to the origin of the primary antibody for instance when utilising 
MBP antibody which is donkey anti-rat, the secondary antibody would be either FITC Donkey anti-
rat or CY3 Donkey anti-rat. Finally, each well was washed with PBS three times for five minutes 
each.  
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Primary antibodies Nestin (mouse) 
Sox-2 (rabbit) 
TUJ-1 (rabbit/ mouse) 
GFAP (rabbit/ mouse) 
MBP (rat) 
Secondary antibodies FITC Donkey anti-mouse 
FITC Donkey anti-rabbit 
FITC Donkey anti-rat 
CY3 Donkey anti-mouse 
CY3 Donkey anti-rabbit 
CY3 Donkey anti-rat 
AMCA Donkey anti-rabbit 
Table 2.2: Antibodies used in ICC. 
Each construct was incubated for a further hour with a solution of 2 µg/mL Hoechst in PBS to allow 
nuclear staining. This was washed three times with PBS before being mounted on to a microscope 
slide with Vectashield and covered with a coverslip. 
2.5.8 2D and 3D imaging of cells in DuraGenTM 
All quantitative imaging was carried out using an Axio Observer.Z1 in combination with an AxioCam 
MRm (black and white camera) with Zen two (blue edition) software. For all assays five fields were 
selected at x200 magnification as demonstrated in figure 2.4. A stack of images was taken as the 
focus moved upwards to produce a Z-stack; this was carried out at each field with the interval fixed 
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at 5µm between each image (figure 2.4). The top and bottom of the stack was allocated when the 
last visible cell went out of focus.   
 
Figure 2.4: Demonstration of acquisition of 3D Z-stack images for quantification including allocation 
of fields for analysis termed plane of analysis (PoA).  
2.5.9 Quantitative analysis of images 
Quantification was carried out utilising ImageJ free software. Each field contained around 10-15 
images which were loaded onto the ImageJ software as a stack allowing quantification throughout 
the layers of the 3D image. Cell nuclei were counted using the cell counter plugin for each field. For 
each assay cells positive for the antibody in question were counted. For live-dead assays, cells 
positive for calcein (green) were counted and nuclei positive for ethidium homodimer-1 (red) were 
counted. There was some bleed through from ethidium homodimer-1 which produced fluorescence 
into the green channel at high exposures. The exposure was set so the bleed-through was minimal 
across all channels. Then this exposure was used for all live-dead imaging. 
DuraGenTM 
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For quantification of axon length, each TUJ1 field was surveyed for axons extending within the same 
plane. Often due to the 3D nature of the construct axons would transverse the layers of the stack 
making measurements difficult. Axons were only selected for measurement if the cell body and full 
length of the axon could be visualised in one plane. In future experiments confocal microscopy may 
be employed to generate 3D images of the construct within which axonal length measurements can 
be made in all directions. Of the axons that met the stated criteria, the freehand line tool in ImageJ 
was utilised to mark from the cell body to the furthest point of the axon, following its curvature. 
This distance was measured. From each DuraGenTM slice made up of images from five fields, axons 
from 30-63 neurons were measured. This was carried out for samples stained with TUJ1 at day 
eight, day 12 and day 16. 
The cellular distribution was quantified in two planes, horizontal and vertical. The horizontal 
analysis was carried out by counting the number of nuclei per field. There were five fields per 
DuraGenTM sample as described above. The average number of cells per corner field or central field 
were calculated to decipher if there was a preferential distribution in one of the sections (figure 
2.5).   This was carried out at 48 hours and eight days. Analysis of the vertical distribution was also 
carried out by imaging cell nuclei. Z-stacks were imaged at 5µm intervals. The top and bottom of 
the matrix was defined as the point where the first/ last fibre was in focus using phase. Nuclei per 
image were counted and converted to a percentage of the total number of images in that z-stack. 
The average number of cells at each one percent interval was calculated (figure 2.5). 
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Figure 2.5: Schematic representing how the distribution analysis was carried out. The red schematic 
represents the method for analysing the distribution of cells in the horizontal plane. The blue 
schematic represents the method for analysing the distribution of cells in the vertical plane. 
2.5.10 Statistical analysis 
At each time point for each experiment where DuraGenTM was investigated the mean; standard 
deviation and standard error were calculated of the quantified percentages. All results are given as 
the mean ± the standard error of the mean. Furthermore, to establish if there was a difference 
between the lower and higher cell seeding density in cell viability at 24 hours a two sample T test 
was used to compare the means. A two sample T test was also used to compare the proliferation 
rates of cells at 24 hours and eight days. When analysing the cell viability or cell type proportions 
at the three different time points a one-way analysis of variance (ANOVA). For comparison of axon 
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length at the three different time points again a one-way ANOVA with Tukey and Fisher post hoc 
multiple comparison tests were utilised. To compare the spatial distribution of cells in both the 
horizontal and vertical planes, one-way ANOVAs were used. All statistical tests were performed 
using MiniTab software.  
2.6 Genetic engineering of NSCs using MNPs with magnetofection and 
minicircle DNA vectors  
2.6.1 Producing mcGFP 
mcGFP were used to allow assessment of levels of transfection in NSCs. mcGFP were produced by 
Dr Sarah Harris in the Neural Tissue Engineering group. mcGFP were produced using the parental 
plasmid pMC.EF1-MCS-IRES-GFP-SV40PolyA and the MC-EasyTM Minicircle DNA Production kit.  
100ng of parental plasmid was transformed into Escherichia coli (strain ZYCY10P3S2T) by heat-
shock. E. coli cultures were grown on LB agar plates containing 50 µg/mL kanamycin for 16h at 37°C. 
Three to five colonies were selected and cultured in LB broth containing 50 µg/mL kanamycin for 
16 h at 37°C and 250 rpm. To ensure the parental plasmid was present in the bacteria a QIAprep 
miniprep kit was used followed by a restriction digest using EcoRI. Gel electrophoresis was 
performed to confirm the size of the plasmid DNA. All electrophoresis was performed using 1% 
agarose in 1xTAE buffer containing 0.5µl GelRed for 120 minutes at 100V.  
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Figure 2.6: DNA minicircle production from the parental plasmid (218) .  
After confirmation of successful transformation, 200 mL of MC-EasyTM Growth Medium was 
inoculated with E. coli and cultured for 16 hours at 30°C and 250rpm. pH and optical density 
(600nm) were measured and for pH 7 and OD600 = 0.6-0.8, 400 mL of arabinose containing MC-
EasyTM Induction Medium was added. The broth was incubated at 30°C and 250 rpm for a further 
five hours and 30 minutes to liberate the minicircle from the parental backbone (figure 2.6). 
Confirmation of the presence of a plasmid the correct expected size for mcGFP was performed using 
a miniprep kit and restriction digest (EcoRI as previously described). Bacterial cells from the 
remaining broth were pelleted for harvest by centrifugation at 3220 x g and 4°C for 20min per 50 
mL broth (300 mL broth into one single pellet). A QIAprep maxiprep kit was used to isolate mcGFP 
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from bacteria pellets as per the manufacturer’s instructions with the following amendments: 20 mL 
of Buffers P1, P2 and P3 were used. Successful isolation of mcGFP using the maxiprep kit was 
confirmed via restriction digest using EcoRI as previously described (figure 2.7). The concentration 
of the mcGFP solution was confirmed using spectrophotometry prior to each transfection. 
 
Figure 2.7: Gel electrophoresis demonstrating mcGFP at the correct size after restriction digest 
(arrow). Image was taken by Dr Sarah Harris. 
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2.6.2 Magnetofection of NSCs 
The method of transfection of neurospheres used here has previously provided efficient 
transfection (195,217). NSCs were passaged after reaching confluence and 500 µL of a single cell 
suspension at 1 x105 cells/mL was added to each well of a 24-well Nunc non-treated multidish. NSCs 
were allowed 24 hours to form neurospheres prior to transfection. NeuroMag, a commercial MNP 
was used for all transfections. mcGFP and NeuroMag particles were suspended in a solution of 3:1 
DMEM: F12 and incubated for 20 minutes to allow the formation of complexes. It was ensured that 
no further mixing took place as this can dissociate the complexes. 50µl of solution was added to 
each well for transfection containing 125ng of mcGFP and 0.435µl of NeuroMag iron oxide 
nanoparticles (a ratio used previously (212)), 50µl of the same DMEM: F12 solution without DNA or 
nanoparticles was added to each control well.  
Each plate was then placed on top of a nanoTherics magnefect-nano 24-magnet array system 
(figure 2.8). The programme was set to F=4Hz to produce an oscillating field for 30 minutes. The 
plate was then removed and placed at 37°C in 5% CO2/ 95% humidified air. After 16 hours 
transfection of neurospheres was confirmed using an Axio Observer.Z1 in combination with an 
AxioCam MRm with Zen two.  
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Figure 2.8: nanoTherics magnefect-nano 24-magnet array system used in magnetofection of NSCs. 
2.7 Approaches to optimise method of achieving a 3D construct supporting 
growth of transfected NSCs 
Multiple methods of constructing a biomaterial scaffold-genetically engineered cell construct have 
been used previously. It was therefore imperative to establish the most effective method of forming 
a DuraGenTM-genetically engineered NSC construct. The flowchart demonstrates the multiple steps 
of optimisation that were required to reach the method used for the main research in chapter four 
(figure 2.9). 
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Figure 2.9: Flowchart of optimisation experiments to produce a genetically engineered cellular 3D 
construct. 
2.7.1 Seeding single transfected cells into DuraGenTM 
Initially, in order to follow the DuraGenTM seeding protocols of section 2.5.1. NSCs were dissociated 
24 hours after transfection (for details of dissociation see section 2.2.2). NSCs were resuspended at 
the lower density of 5x105 cells/ mL due to low cell numbers post passage and seeded directly on 
to DuraGenTM slices of 250µm. They were then incubated for a further 24 hours before visualisation 
under light microscopy.  
After 24 hours post seeding of transfected single cells into DuraGenTM the matrix appeared to have 
disintegrated. To investigate the conditions the DuraGenTM samples had been exposed to, the pH 
of each condition medium and some standard stock medium was measured using pH indicator 
strips.  
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2.7.2 Seeding transfected neurospheres into DuraGenTM  
Following the failure of single cell seeding of transfected NSCs, removing the second dissociation 
step and simply collecting and seeding the transfected NSCs as neurospheres onto the DuraGenTM 
was investigated. After transfection had been confirmed, at 24 hours the neurosphere suspension 
was added to the construct. The optimal method for this was assessed; either (1) neurospheres 
transferred directly on to DuraGenTM in the same slow, dropwise fashion as section 2.5.1, or (2) the 
DuraGenTM slice was added to the neurosphere suspension allowing cells to infiltrate the collagen 
matrix (figure 2.10). No difference in cell numbers was observed between the two methods 
therefore method one was used for the full characterisation of the construct. To avoid any further 
loss of the material all attempts to control or increase the density were precluded.  
Figure 2.10: Schematic representing two techniques to achieve DuraGenTM containing genetically 
engineered NSCs. 
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2.7.3 In-situ engineering of NSCs 
In order to simplify the 3D construct transfection protocol, a method to transfect the NSCs within 
the matrix was investigated. For the purpose of this thesis the method involving transfecting NSCs 
that are within the DuraGenTM construct was termed in-situ engineering. The benefit of this method 
is that it simplifies the process by removing a step. NSCs were seeded on to DuraGenTM at 250µm 
thickness and allowed to adhere to the material over the following 24 hours. Equivalent volumes 
of transfection reagents as described in section 2.6.2 were added to each well containing a cellular 
DuraGenTM sample. Control wells were treated identically except mcGFP and NeuroMag were 
omitted. Samples were subjected to one of three different conditions: (1) Oscillating magnetic field 
(F=4Hz), (2) static magnetic field (F=0Hz), or (3) no field. Plates were visualised at four, six, 16 and 
24 hours to confirm transfection utilising an Axio Observer.Z1 in combination with an AxioCam 
MRm with Zen two. This method was unsuccessful initially; therefore, re-transfection without a 
magnetic field was carried out for all DuraGenTM samples. 
3.7.4 Optimisation of anti-GFP ICC in two 2D and 3D 
In previous studies utilising GFP the visually detectable levels of expression have been lower than 
the true value. These studies used an anti-GFP antibody to detect cells that did not demonstrate 
GFP expression under fluorescent microscopy but were in fact producing GFP. Figure 2.11 
demonstrates the increased sensitivity for GFP expression provided by the use of anti-GFP antibody. 
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Figure 2.11: Anti-GFP antibody increases the detection of transfected NSCs. Inset demonstrates 
GFP expression in transfected NSCs after 48 hours (white arrows). Main image represents anti-GFP 
antibody robustly detecting NSCs expressing low levels of GFP (red arrows). Scale bar = 25µm. 
To detect GFP in the DuraGenTM construct, the anti-GFP antibody was used. The method for ICC 
described in section 2.5.7 was utilised. After incubation with the primary antibody: anti-GFP at a 
dilution of 1:700, CY3 donkey anti-rabbit at 1:200 was used for secondary staining. Later the 
concentration of primary antibody was reduced to 1:1000.  
Due to high background staining on the control samples and transfected samples, the exposure of 
the images was set so that control samples did not display background GFP staining. Exposure was 
kept constant throughout.  
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2.7.5 Trials of live cell ICC on transfected NSCs in DuraGenTM 
Live imaging of transfected NSCs in DuraGenTM demonstrated an increased intensity of GFP 
expression than when the same samples were fixed and imaged. Therefore, live cell ICC was 
attempted to examine whether omitting the fixation step could improve visualisation of the GFP 
expression. GFAP antibody was diluted (1:500) in pre-warmed differentiation medium. All medium 
was removed from each well and 400μl of the primary antibody dilution was added. This was 
incubated (37˚C) for 30 minutes before being washed off gently with medium. CY3 secondary 
antibody also diluted in medium (1:200 in 400μl) was added to each well. The constructs were 
observed regularly and at three hours no staining was evident. The protocol was revised, adding in 
one-hour incubation of primary antibody and no definitive staining was evident.  
2.8 Characterisation of transfected NSCs within a surgical material 
2.8.1 Magnetofection of NSCs with GFP 
For characterisation purposes NSCs were transfected according to the methods stated in section 
2.6.2. 
2.8.2 Transfer of transfected NSCs to DuraGenTM  
24 hours after transfection GFP expression was confirmed using a Zeiss fluorescent microscope. 
Following confirmation of transfection, each well containing neurospheres suspended in 500µl of 
neurosphere medium were transferred via Gilson pipette onto pre-prepared DuraGenTM slices of 
250µm thickness (see section 2.4.2 and 2.5.1 for details of DuraGenTM preparation). Transfected 
neurospheres and control neurospheres were transferred into corresponding wells containing 
DuraGenTM in a fresh 24-well plate to maintain continuity of conditions (figure 2.12). Constructs 
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were then incubated at 37°C in 5% CO2/ 95% humidified air until their relevant assay time point 
(table 2.3). 
 
Figure 2.12: Schematic depicting the optimised process of achieving transfected NSCs within the 
DuraGenTM matrix. 
2.8.3 Anti-GFP ICC 
After fixation in 4% PFA (section 2.5.6), ICC protocols were as described in section 2.5.7. Briefly, 
constructs were incubated in blocking solution consisting of 5% NDS-0.3% triton X-100 in PBS. 
TurboGFP antibody was added at a concentration of 1:1000 and incubated at 4°C overnight. After 
three five-minute washes and subsequent blocking, CY3 (donkey anti-rabbit) was added diluted 
1:200 in blocker for three hours at room temperature. Constructs were washed again, and the 
nuclei stained with Hoechst dye (as in section 2.5.7). 
2.8.4 Investigating cell viability, proliferation and morphology 
All assays were carried out in accordance with the methods given in sections 2.5.4-7 unless stated 
otherwise. Assay time points are given in table 2.3. Day 0 is the day of transfection and day one is 
when cells were added to the constructs. Both timings are given for clarity. For differentiation, 
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medium was changed at two days post transfection and one day post seeding into DuraGenTM (see 
section 2.5.2 for details of differentiation method). 
Assay Time point post transfection  Time point post seeding into construct 
Live-dead 2 days 1 day 
EDU Proliferation  2 days 1 day 
Nestin (NSC marker) 2 days 1 day 
Sox-2 (NSC marker) 2 days 1 day 
Anti-GFP 2 days 1 day 
GFAP/TUJ1/MBP 7 days 6 days 
GFAP/ TUJ1/ MBP 9 days 8 days 
Table 2.3: Time points for assays utilised to assess the safety and efficacy of transfection of NSCs 
and transfer to collagen matrix. 
2.8.5 2D and 3D imaging of transfected cells in DuraGenTM 
Imaging was carried out following the method outlined in section 2.5.8.  
2.8.6 Quantitative analysis of images 
All fields both transfected and control were analysed by the method given in section 2.5.9. 
Transfected cells were identified by their green fluorescent stain associated with a cell nucleus. 
Although utilising NSCs within the neurosphere format has many benefits, one associated drawback 
is the reliability of cell counts due to the density of cells within the neurosphere. Previous studies 
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have dissociated the neurospheres to gain more accurate counts. Due to the neurospheres being 
within DuraGenTM in this study, it was not possible to dissociate the cells therefore transfection 
efficiency was based on the existence of at least one transfected NSC within the sphere. Proportions 
of neurospheres with at least one transfected NSC were counted. 
2.8.7 Statistical analysis 
All transfected and control groups were compared using MiniTab software. Where there were two 
groups for comparison, transfected versus control, a two sample T-test was performed. If there 
were multiple comparison groups, for example the differentiated cell type proportions in 
transfected versus control, two sample T-tests were performed for each comparison group.  
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Chapter 3:  Investigating neurosurgical grade 
materials for the encapsulation of NSCs 
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3.1 Introduction 
Neurosurgical grade materials offer a potential pre-approved biomaterial scaffold solution for stem 
cell delivery. There are multiple surgical materials available, each composed of different polymers 
and with distinct physical properties. Some are liquids or gels and others solid structures. Major 
pharmaceutical companies produce these materials on a large scale therefore translation of a stem 
cell therapy encapsulated within a surgical material to the clinical environment becomes more likely 
due to the existing infrastructure. The following two materials were selected for analysis in this 
chapter. 
Firstly, DuraGenTM has demonstrated significant potential for the encapsulation of other cell types 
(details in section 1.3.6). To the best of our knowledge it appears DuraGenTM has never been tested 
for its capacity to allow the survival of NSCs or their differentiated progeny.  Although evidence 
exists demonstrating DuraGenTM use in PNS implants and to support cortical neuron growth (details 
in section 1.3.6), it has never been considered as a CNS therapeutic option beyond its current 
indications for duraplasty. Hence, this chapter study aims to establish whether DuraGenTM can 
support the growth of NSCs and allow them to differentiate to determine its utility as an 
implantable encapsulating cellular delivery device for the treatment of SCI.  
Secondly, DuraSealTM was selected due to its properties and similarities with previously successful 
(unapproved) pre-clinical cell transplant materials (details in section 1.3.7). Additionally, it offers 
the benefit of being a liquid format. Although DuraSealTM has shown promise in PNS graft, it has 
never been used to deliver any transplant cell type. Moreover, DuraSealTM has never before been 
suggested for use in CNS therapies beyond its indication as a dural sealant. Our study intends to 
investigate DuraSealTM as a potential scaffold for the growth and differentiation of NSCs with the 
intention of utilising this as an injectable material for cell encapsulation for the treatment of SCI. 
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3.2 Aims and objectives 
Given the current lack of availability of a successful, FDA-approved substrate for NSC delivery to the 
site of SCI, this chapter will investigate the potential of two FDA-approved surgical materials to act 
as cell encapsulation devices for NSC transplantation. The specific objectives for this chapter are as 
follows: 
I. To carry out pilot studies on DuraGenTM and DuraSealTM to make an initial assessment of 
their capacity to support 3D NSC growth. 
II. To characterise DuraGenTM and DuraSealTM’s structures using high resolution SEM to 
identify the pore size. 
III. To optimise culture parameters for cell growth, ICC and microscopic analysis in DuraGenTM. 
IV. To establish whether DuraGenTM has any adverse effects on key cellular properties of NSCs: 
namely, viability, proliferation and differentiation. 
V. To determine the 3-D spatial distribution of cells within DuraGenTM. 
3.3 Results 
3.3.1 DuraSealTM does not support 3D cell growth 
Preliminary investigations into the potential use of DuraSealTM proved that it is unlikely to be able 
to support cell growth. After standard application according to the manufacturer’s guidelines, 
DuraSealTM formed a gel-like material within the tube it was injected into. After the addition of food 
colouring dye to DuraSealTM there was no immediate evidence of permeation of the dye through 
the gel. 24 hours later no change was visible and there was a distinct DuraSealTM-dye interface 
apparent (Figure 3.1c). As the dye appeared unable to diffuse through the DuraSealTM matrix, the 
likelihood of the material supporting cellular infiltration or medium circulation becomes negligible. 
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This idea was corroborated by SEM which demonstrated a lack of porosity in the DuraSealTM matrix 
(Figure 3.1d). This surgical material was therefore deemed unlikely to allow penetration of or 
provide protective encapsulation of transplantable cells. This material was rejected from further 
experiments in my thesis on this basis. 
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Figure 3.1: DuraSealTM does not support permeation of liquid (a) DuraSeal
TM
 product comes as two 
separate components (158). (b) DuraSeal
TM
 is licensed for use as a dural sealant post spinal surgery 
(219). (c) DuraSeal
TM
 (blue) does not demonstrate permeation of a dye (red) after 24 hours. The 
black line indicates the DuraSeal
TM
-dye interface.  (d) SEM demonstrating the lack of porosity in 
DuraSeal
TM
. Scale bar = 1µm. 
DuraSealTM 
Dye 
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3.3.2 DuraGenTM supports NSC growth 
DuraGenTM demonstrated the ability to rapidly (within 5-10 seconds) absorb medium (figure 3.2a-
b) when applied to a dry sample. From a visual assessment, ca 25-40% expansion of the material 
was observed as the medium was absorbed. Under light microscopy DuraGenTM demonstrated an 
obvious, highly porous structure (figure 3.2c). Pore size appeared variable on visual inspection. SEM 
of DuraGenTM confirmed its highly porous structural network (figure 3.2e-f).  The pore diameter 
was highly variable with an average size of 25.9 ± 14.3 µm. When seeded with dissociated NSCs, 
initial light microscopy showed cells infiltrating the material’s pores. In order to prove that 
DuraGenTM can act as a cell delivery matrix, it was important to obtain early evidence that cells will 
adhere to the matrix. After ICC on pilot DuraGenTM samples, the adhesion of NSCs to the matrix was 
evident (figure 3.2d) and there was an irregular cell distribution throughout the material with no 
obvious pattern.  
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Figure 3.2: Porous DuraGen
TM
 structure demonstrates cell adherence (a) dry DuraGen
TM
 sample 
before processing (b) DuraGen
TM
 after application of media demonstrates absorption with evidence 
of swelling. (c) DuraGen
TM
 under light microscopy demonstrates an obvious porous structure. (d) 
Balls of NSCs adhere to the DuraGen
TM
 structure. (e) and (f) SEM at x100 magnification and x1000 
magnification respectively show the porous structure of DuraGen
TM
. 
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3.3.3 Preliminary experiments established optimal parameters for cell growth, ICC and microscopic 
analysis in DuraGenTM 
3.3.3.1 DuraGenTM thickness optimisation 
DuraGenTM seeded at full thickness c.a. five millimetres demonstrated presence of cells at the cut 
edges of the materials but none centrally (Figure 3.3a). When the thickness was reduced to 500µm, 
250µm and 100µm it was observed that NSCs were distributed more evenly throughout the 
DuraGenTM sheet. It was evident that 250µm was the most suitable for cell growth and visualisation 
with ICC (Figure 3.3c). 250µm slices allowed the best visualisation of cell morphologies of all three 
slice thicknesses and also contained more cells than the thinnest slice (100µm). By contrast, 500µm 
sheets obscured clear visualisation of cellular morphologies (Figure 3.3b). Additionally, DuraGenTM 
sliced to a thickness of 100µm contained fewer cells (Figure 3.3d) and appeared more friable on 
handling. On this basis DuraGenTM was processed at 250µm for all further experiments.  
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Figure 3.3: Early pilot studies show need for optimisation protocols. (a) Image courtesy of Farhana 
Chowdhury: Human astrocytes growing at the edge of the full thickness DuraGen
TM
 slice. Red line 
depicts the edge of the material. The edge and centre of the matrix are indicated. (b) 500µm slice 
of DuraGen
TM
 obscures NSCs growing within matrix at 24 hours; (c) 250µm slice of DuraGen
TM
 allows 
optimal visualisation of NSCs in 3D within the matrix at 24 hours; (d) the 100µm slice of DuraGen
TM
 
shows few NSCs within the matrix at 24 hours. Scale bar = 50μm in all images. 
3.3.3.2 Optimal cell seeding density for DuraGenTM 
Pilot investigations into optimal cell seeding density for DuraGenTM demonstrated higher numbers 
of cells adhered to the matrix, on visual inspection, with a higher seeding density (1x106 cells/mL) 
compared to the lower seeding density (5x105 cells/mL) (figure 3.4a-b). There was no significant 
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difference in cell viability at 24 hours after seeding between low and high seeding density groups 
(p-value=0.574, two sample T-test, n=3) (figure 3.4c). Therefore, it was established that 1x106 
cells/mL would be most suitable for all further analysis. 
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Figure 3.4: High cell viability in both high and low-density samples. (a) Fewer cells adhered to 
DuraGen
TM
 matrix at lower seeding density of 5x10
5 
cells/mL. (b) High number of cells adhered to 
DuraGen
TM
 with a higher seeding density of 1x10
6 
cells/mL. The corresponding nuclei are displayed 
beneath images (a) and (b). Scale bars = 25μm. (c) Bar graph displays no difference in the cell 
viability at differing densities (p-value > 0.05, two-sample T-test, n=3). 
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3.3.3.3 ICC protocols required optimisation for use with the DuraGenTM matrix 
Preliminary experiments utilising standard monolayer ICC protocols did not sufficiently stain cells 
in the centre of the material. Moreover, the DuraGenTM fibres were also found to be stained 
confounding the interpretation of results (figure 3.5a). Briefly, standard ICC protocols involve 
overnight primary antibody incubation and a two-hour secondary antibody incubation. All washes 
are carried out three times for five minutes each. Therefore, the standard protocols utilised for 
collagen gels previously used in the laboratory were trialled with incubation times and washes 
increased (for details see section 2.5.7). After these adjustments were made, cell staining increased 
whilst background fibre staining decreased allowing better visualisation of cell morphologies. 
Vectashield with DAPI was applied to the matrix prior to microscopic analysis but this led to fibre 
staining also (figure 3.5b). By contrast, when incubated with Hoechst dye for one hour and washed 
three times this fibre staining decreased.  
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Figure 3.5: DuraGen
TM
 fibres stained by ICC protocol requiring experimental optimisation (a) NSCs 
in DuraGen
TM
 at 48 hours with significant DuraGen
TM
 fibre staining. Arrows indicates DuraGen
TM
 
fibres. (b) Nuclei of differentiated cells at day eight in DuraGen
TM
 stained with Vectashield with DAPI 
demonstrating fibre staining. White arrows indicate the DuraGen
TM
 fibres, red arrow indicates the 
edge of the DuraGenTM matrix. Scale bars = 100μm. 
3.3.4 DuraGenTM does not have adverse effects on the key cellular properties of NSCs 
3.3.4.1 High NSC viability in DuraGenTM across all time points  
To assess the safety of the biomaterial for NSCs, cell viability assays of live and dead cells along with 
counts of pyknotic nuclei were carried out at an early (24 hours), intermediate (eight days) and late 
time point (12 days). Pyknosis (defined as the condensation of chromatin within the nucleus caused 
by necrosis or apoptosis) was detected by evidence of a hyperdense, small and/or fragmenting 
nucleus (220) (figure 3.6b). NSCs and differentiated cells displayed high proportions of live cells 
across all time points (≥ 87.0 ± 3.74%) and a low proportion of pyknotic nuclei (≤ 7.48 ± 1.51%) 
(figure 3.6a-d). There was no significant difference between the proportions of live cells in 
DuraGenTM at any time point (p-value = 0.179, one-way ANOVA, n=3). There was no significant 
48 hours in DuraGenTM 8 days in DuraGenTM 
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difference in the proportions of pyknotic nuclei at all time points (p-value = 0.297, one-way ANOVA, 
n=3). 
Figure 3.6: High cell viability in DuraGen
TM 
across all time points. (a) Representative fluorescence 
image at 24 hours demonstrating live cells stained with calcein and dead cells stained with ethidium 
homodimer-1 (arrows indicate dead cells), the insert demonstrates nuclei stained with Hoechst dye. 
Scale bar = 50μm. (b) Example pyknotic nucleus (arrow) surrounded by healthy nuclei. Scale bar = 
20 μm. (c) Bar graph displays consistently high cell viability across all time points. The difference 
between time points was not significant (p-value > 0.05, one-way ANOVA, n=3). (d) Bar graph shows 
low proportion of pyknotic nuclei across all time points. The differences between time points were 
not significant (p-value > 0.05, one-way ANOVA, n=3). 
24 hours  24 hours  
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3.3.4.2 NSCs maintain stem cell phenotype in DuraGenTM matrix  
The safety of a transplant substrate is often assessed by its ability to maintain the cells in a desired 
phenotype. In DuraGenTM, a high proportion of nuclei were positive for nestin, a NSC cytoskeleton 
marker (93.1 ± 2.84%) and a similarly high proportion of nuclei were positive for Sox-2, a NSC-
specific transcription factor (95.5  0.42%), both at 48 hours. Cells demonstrated clear NSC 
morphologies with processes and were associated with rounded nuclei. NSCs were randomly 
orientated with no obvious pattern to the direction of processes. Processes extend into multiple 
planes within the matrix requiring a Z-stack imaging technique to fully detect them (figure 3.7 and 
Video 3.1).  
 
Figure 3.7: NSCs retain their stem cell phenotype in DuraGenTM. Representative fluorescence 
image (a) of a complex network of NSCs, inset: nuclei (Video 3.1 in supplementary materials). 93.9 
 2.84% of cells positive for nestin at 48 hours (n=3). Scale bar = 50μm. Representative fluorescence 
image (b) of a high level of Sox-2 staining of NSCs in DuraGenTM. 95.5  0.42% of cells were positive 
for Sox-2 at 48 hours (n=3). Scale bar = 10μm.  
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3.3.4.3 DuraGenTM allows proliferation of NSCs and astroglial lineage cells 
NSCs are self-renewing, hence it was important to establish if DuraGenTM would support the 
proliferation of these cells. At all time points investigated, there was evidence of cell proliferation 
(figure 3.8c). At 24 hours, 25.6 ± 4.07% of cells expressed EdU (figure 3.8a). This decreased to 7.21 
± 1.41% at eight days once the cells had differentiated. The difference between the proliferation 
rate at 24 hours was statistically different to at eight days (p-value = 0.008, two sample T test, n=3). 
The majority of cells (ca. 71.8%) that showed EdU labelling in the differentiated population were 
astroglial lineage cells (GFAP positive) (figure 3.8b). Cells that proliferated and did not stain for 
astrocytic marker (EDU positive and GFAP negative) are likely to be undifferentiated NSCs.  
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Figure 3.8: Cells proliferating at 24 hours and at eight days in vitro. Representative fluorescence 
images demonstrating (a) proliferation of NSCs (nestin) observed at 24 hours in DuraGen
TM
, arrows 
indicate proliferating NSCs, and (b) proliferation of differentiated cells. Arrow indicates proliferating 
astrocyte (GFAP). (c) 25.6  4.07% of cells proliferated after 24 hours and 7.21  1.41% of cells after 
eight days proliferated (EdU) within a 16-hour period. Statistical difference was analysed between 
the two time points and is: **p-value < 0.01 (two sample T-test, n=3). Scale bar = 50μm.  
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3.3.4.4 DuraGenTM supports differentiation of NSC into astroglial lineage cells, neurons and 
oligodendrocytes 
Six days following differentiation induction (eight days in DuraGenTM) three classes of daughter cells 
– neurons, astroglial lineage cells and oligodendrocytes were observed (figure 3.9). The highest 
proportion (79.6 ± 6.28%) were that of astroglial lineage cells which demonstrated normal stellate 
morphologies. 18.6 ± 5.10% of cells were of the neuronal lineage, staining for TUJ1. Neurons 
demonstrated short processes at this early time point. Processes extended in multiple directions 
without an obvious pattern or directionality in growth. The smallest proportion of cells were 
oligodendrocytes, 2.12 ± 0.96% were positive for MBP (figure 3.10). The oligodendrocytes 
demonstrated highly branched morphologies often extending into multiple planes. Some nuclei did 
not stain for any marker, it is hypothesized that these are undifferentiated NSCs.  
Across all time points there was no significant change in the proportion of each cell type, with time. 
Neurons demonstrated evidence of maturation across the time period displaying increasing 
complexity in their networks (figure 3.9). Axon length increased two-fold from day eight to day 16 
(p=0.02, one-way ANOVA with Tukey and Fisher post hoc multiple comparison tests, n=3) (figure 
3.11a-c). Triple staining of DuraGenTM revealed all three cell types in the same field (data not 
shown). 
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Figure 3.9: DuraGen
TM
 supports maturation of each cell type over time. (a) Astroglial lineage cells 
display normal morphology up to 16 days. (b) Axons increase in length and networks increase in 
complexity as time in vitro increases. (c) Oligodendrocytes display branched 3D morphology. Each 
scale bar = 25μm.  
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Figure 3.10: DuraGen
TM
 demonstrated the capacity to support growth of all three types of 
daughter phenotypes. (a) The proportions of each daughter cell type remain the same. (b) The 
absolute numbers of each cell type remain the same across the time points. There was no significant 
difference in proportion of each cell type across all time points (p-value > 0.05, one-way ANOVA, 
n=3). 
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Figure 3.11: DuraGen
TM
 allows extension of axons through matrix. (a) Short processes of neurons 
growing in DuraGen
TM
 at eight days. (c) Elongated processes of neurons growing in DuraGen
TM
 at 
16 days. (c) Axon length increased two-fold from day eight to day 16. Statistical difference is: *p-
value < 0.05 vs day 8 (one-way ANOVA with Tukey and Fisher post hoc multiple comparison tests, 
n=3).  Scale bar = 25μm. 
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3.3.5 3-D spatial distribution of cells throughout the matrix 
The distribution of the NSCs (48 hours) and later the differentiated cells (eight days) within the 
DuraGenTM matrix were investigated to study the distribution within the matrix. Within each field 
viewed microscopically, cells appeared to be grouped together. In some fields they followed the 
patterns of the fibres of the DuraGenTM matrix.  
When viewing cellular distribution across the matrix in the horizontal plane (figure 3.12), cells were 
observed in all sections of the matrix and there was no significant increase in the number of cells in 
any specific region in NSCs (48 hours) or differentiated cells (eight days) (p>0.05, one-way ANOVA, 
n=3) (figure 3.13a-b). Previous studies investigating collagen materials have detected a high 
number of cells sinking to the bottom of the material (221). In DuraGenTM cells did not appear to 
sink to the base of the matrix but were distributed throughout the depth of the matrix at 48 hours 
and eight days (figure 3.13c-d).  
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Figure 3.12: No difference in the spatial distribution in the horizontal or vertical plane. (a) and (b) 
represent the average number of cells per field taken in each of the five spatial locations. No section 
of the material showed preferential distribution of NSCs (48 hours) or differentiated NSC (eight days) 
growth (p-value >0.05, one-way ANOVA for 48 hours and eight days, n=3). (c) and (d) represent the 
average number of cells per PoA considered to be each slice of a Z-stack. The cells were distributed 
throughout the depth of the matrix at both 48 hours and eight days (n=3). Fluorescent images (e-l) 
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demonstrate a z-stack at eight days with nuclei distributed throughout the DuraGenTM matrix in 3D. 
Scale bar = 50µm. 
3.4 Discussion 
3.4.1 DuraGenTM supports NSC growth, proliferation and differentiation 
We have demonstrated for the first time the capacity of a neurosurgical, collagen-based biomaterial 
to support the growth of NSCs, supporting the concept that it can be used as a cell delivery matrix. 
This chapter demonstrates that DuraGenTM can successfully support a population of NSCs without 
any significant impact on the cellular properties assessed. Importantly, high survival, maintenance 
of stem cell phenotype, continued proliferation and differentiation into all three daughter cell types 
within the material demonstrates its capacity to act as a protective matrix for the delivery of stem 
cells. To the best of our knowledge, this also represents the first time a surgical grade material has 
been shown to support a major neural cell transplant population. 
The differentiation profile of NSCs in DuraGenTM did not widely differ from that previously seen on 
glass, thought to be the gold standard for in vitro culture, and from that of other types of collagen. 
Table 3.1 displays the differing differentiation profiles on a range of materials. When comparing 
DuraGenTM to monolayer NSC culture on glass and another type one collagen, rat tail collagen, there 
were similar proportions of astroglial lineage cells, neurons and oligodendrocytes. Rat tail collagen 
is a soft material. We do not know the stiffness of DuraGenTM.  Softer materials have been 
previously shown to promote neurogenesis (222). Neurogenesis is important when considering 
clinical translation. As described in section 1.1.4, the spinal cord is a ‘non-permissive zone’ for 
neuronal differentiation (24,28). Therefore, if neuronal differentiation can occur in DuraGenTM it 
might counteract the non-permissive environment at the SCI site. 
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 Astroglial lineage cells Neurons Oligodendrocytes 
DuraGenTM  79.6% 18.6% 2.12% 
Glass  82% 12% 4% 
Rat tail collagen 80% 16% 4% 
Table 3.1: Differentiation profiles of NSCs on a variety of material substrates. Figures for glass and 
rat tail collagen are from (223). 
3.4.2 The pore size of DuraGenTM allows infiltration of NSCs 
The pore size in DuraGenTM was highly varied and had an average size of 25.9 ± 14.3 µm. The average 
size of an NSC is approximately 15µm, hence they can easily pass through the material’s pores.  
There is a broad range of pore size within biomaterial scaffolds. A 2mg/ml collagen gel has a pore 
size of 2.84 ± 0.94µm and a fibrin gel has a pore size of 1.69 ± 0.33 µm (224). Other materials utilised 
for cell transplantation have a nanoporous structure, such as alginate which has pores 5.2 – 7nm in 
size (225). Chitosan scaffolds and PEG hydrogels have larger pore sizes of 30-90 µm and 41-134 µm 
respectively (226,227). Brauker et al suggest that for cell encapsulation, a scaffold must have a pore 
size of 0.8-8µm (228). Lim et al describes a necessity for larger pore sizes, finding that greater than 
90µm increased cell infiltration and vascularisation (226). Nonetheless, Integra LifeSciences report 
that DuraGenTM allows vascularisation to occur (142). The large variety in pore sizes of differing 
biomaterials suggests that none is the gold standard. It is likely that different cell types and different 
applications require different pore sizes. What is evident, is that pore size affects cellular behaviour 
and DuraGenTM, with its mid-range pore size, has demonstrated the ability to support a viable 
population of NSCs. 
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3.4.3 The structure of DuraGenTM produces a random alignment of axons 
DuraGenTM’s fibrous structure has no directionality. The pores are randomly sized and spaced. This 
led to processes of the NSCs growing in all directions with no obvious pattern. When the NSCs had 
differentiated, the axons of the neurons also extended in a random alignment. Random alignment 
of axons could be problematic for the success of a transplant in SCI. For example, a rat contusion 
SCI study found that transplantation of NSCs caused uncontrolled axonal sprouting which led to 
allodynia in the rats (91).  
There are some possible solutions to the alignment of cells within DuraGenTM. Mechanical tension 
placed across the material could encourage linear growth. The matrix is amenable to stretch. 
Alternatively, magnetic alignment of collagen fibres has previously been demonstrated. Here, liquid 
collagen was subjected to a bipolar magnetic field during the setting process. This produced linear 
alignment of the collagen fibres (229). DuraGenTM is a pre-made material, to change the fibre 
alignment it would be necessary to change the manufacturing process. Growth factors encourage 
directional axonal growth. Bonner et al injected neuronal restricted- and glial restricted- precursors 
into dorsal column lesions in rats. After seven days, they injected lentiviral vectors, expressing 
BDNF, 2.5 or 5mm rostral to the lesion. This created a neurotrophin gradient. In the groups, exposed 
to the neurotrophin injection, there was an increase in directional axon growth (230). The use of a 
neurotrophin gradient with DuraGenTM may promote directional axonal growth through the matrix. 
3.4.4 Pre-differentiated implantable neural circuit  
We have for the first time produced a viable culture of the three major cell types of the CNS in a 
neurosurgical grade material. After differentiation induction, astroglial lineage cells, neurons and 
oligodendrocytes were successfully growing within the matrix. All three cell types were visualised 
in the same field. It was unclear whether the cell types were interacting with one another. All three 
cell types were often in close proximity but ICC with fluorescent microscopy could not provide 
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information on cell interactions. For instance, it would be important to discover whether the 
oligodendrocytes were myelinating the axons within the matrix.   
The construct containing these three cell types, a neural circuit, could be transplanted into the site 
of a SCI. There are many benefits of a pre-differentiated implantable neural circuit. Firstly, it 
provides the opportunity to implant post-mitotic cells (neurons and oligodendrocytes) previously 
considered to be challenging to transplant (231). Secondly, pre-differentiated lineage cells have 
shown improved survival and integration into the CNS in rat SCI (96).  
3.4.6 A clinical grade material has the potential to be accelerated to clinical trial 
These initial trials utilising this FDA-approved biomaterial scaffold demonstrate the foundation to 
begin further research into the potential use of DuraGenTM for neuroregenerative therapies. Here 
we investigated two seeding densities and both demonstrated high viability. It is entirely feasible 
that the DuraGenTM matrix could be seeded with a higher density of cells than 1x106 cells/ml to 
increase the numbers of cells delivered for clinical therapy.  
We also utilised samples of DuraGenTM at an optimised thickness of 250µm to achieve the aims of 
this study. In clinical practice, it may be possible to use multiple, thin strips of DuraGenTM at the 
lesion site. SCI lesions are likely to be an irregular shape. It may offer the advantage of 
conformability if the DuraGenTM is sliced to 250µm. To utilise the full thickness of DuraGenTM, an 
improved cell loading technique may be required. Where other researchers have utilised 
DuraGenTM at its full thickness, they have used alternative methods. For instance, Adesida et al 
seeded the matrix with a small of volume of very high-density meniscus fibrochondrocytes and 
allowed these to adhere to the material for 15 minutes. Then, following this incubation time the 
matrix was flooded with medium (147). This method was unnecessary for the aims of this trial but 
offers a different way to improve the cell density and distribution within larger sections of the 
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scaffold. This method may be useful for clinical manufacture. It offers the advantages of improving 
cell attachment so hence conserving precious cell transplant populations.  
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Chapter 4: Genetically engineering NSCs 
within a neurosurgical grade material 
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4.1 Introduction 
A cell transplant population encapsulated within a supportive biomaterial scaffold addresses many 
pro-regenerative goals, such as encouraging axonal regeneration and bridging the cystic cavity. To 
maximise therapeutic benefit, cellular populations can be genetically engineered to produce 
trophic factors increasing the likelihood of enhanced regenerative outcomes. A construct formed 
of a genetically engineered cell population encapsulated within a biomaterial scaffold could 
constitute a single application, combinatorial therapy. To increase the therapeutic benefit of such 
a construct, the utilisation of a pre-approved neurosurgical grade biomaterial to encapsulate the 
cells could generate an implantable ‘superconstruct’ for regenerative applications. A combined 
nanoengineering and surgical biomaterial delivery approach has never been tested. Our study 
intends to investigate the potential of a pre-approved neurosurgical grade biomaterial scaffold, 
DuraGenTM, to encapsulate a transplantable population of NSCs engineered utilising clinically 
applicable magnetofection and minicircle technology. 
4.2 Aims and objectives 
The specific objectives for this chapter are as follows:  
I. To successfully genetically engineer NSCs using magnetofection technology and applied 
magnetic fields to express GFP. 
II. To prove that DuraGenTM can support the growth of a genetically engineered population of 
NSCs. 
III. To test two methods of producing the ‘superconstruct’: ‘engineering in situ’ versus ‘pre-
transfection and cell loading’.  
IV. To assess the efficacy of transfection of NSCs in DuraGenTM. 
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V. To establish if key safety parameters including cell viability, proliferation and differentiation 
are impacted by combining genetic engineering methodologies with DuraGenTM construct 
formation. 
4.3 Results 
4.3.4 Pilot experiment: In-situ engineering method demonstrated limited GFP expression 
The ability to transfect NSCs that have been pre-loaded into the DuraGenTM matrix offers logistical 
benefits for larger scale manufacture. A protocol whereby cells could be grown within the matrix 
and then subsequently engineered could be manufactured more easily than engineering the 
population of cells and then loading into the material. Therefore, the ‘engineering in-situ’ method 
was trialled. After 24 hours post transfection, there was no visually detectable GFP expression in 
any applied field condition. In previous reports of magnetofection on monolayer cultures, NSCs 
expressed GFP after four hours with numbers peaking at 48 hours where ca. 32.2% were transfected 
(223). Re-transfection was carried out with no field for all previous conditions. After a further 24 
hours, a negligible number of cells (<1%) expressed GFP in the repeat transfection experiment 
(figure 4.1). Due to the lack of success demonstrated with this method of transfection, a two-step 
method was investigated next.  
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Figure 4.1: Limited success of in-situ engineering. (a) Two sequential transfections with no 
magnetic field produced no GFP-expression. (b) Low number of NSCs expressing GFP in DuraGenTM 
after two successive transfections with mcGFP, the first with a static magnetic field and the second 
with no field. (c) Initial transfection in an oscillating field, followed by transfection without a 
magnetic field did not produce any GFP-expression. Red arrows indicate neurospheres within 
DuraGenTM. Scale bar in main images = 100µm, insert = 25µm.  
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4.3.5 Pilot experiment: A two-step method could be used to yield genetically engineered NSCs in 
DuraGenTM 
The next step was to trial the ‘pre-transfection and cell loading’ protocol. NSCs were transfected as 
neurospheres in suspension and then subsequently dissociated into single cells for seeding into 
DuraGenTM (for details see section 2.7.1).  
Prior to transfection, neurospheres appeared evenly sized and round under phase microscopy. 
Transfection of neurospheres yielded a high proportion of neurospheres containing at least one 
transfected NSC at 24 hours (94.5 ± 3.62%) (n=3). No transfected cells were seen in any of the 
control conditions (figure 4.2). Post transfection, most neurospheres remained intact with some 
adhering to the base of the well. This also occurred in the controls. 
Figure 4.2: NSCs within neurospheres express GFP. (a) Representative fluorescence image 
demonstrating transfected neurospheres at 24 hours, 94.5  3.62% of neurospheres had at least 
one transfected NSC (n=3). (b) Control neurospheres at 24 hours. Scale bar = 50µm. 
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For this pilot experiment, transfected neurospheres were dissociated and seeded into 250µm 
sheets of DuraGenTM (see methods section 2.5.1). Immediate visualisation revealed GFP-expressing 
NSCs within the matrix. After 24 hours, visualisation under light microscopy revealed that the 
DuraGenTM matrix had disintegrated in both transfected and control conditions (figure 4.3). pH tests 
of the medium revealed pH 8.5 for both transfected and control. The NSCs had been subjected to 
multiple passages within a relatively short space of time. This led to a decreasing number of cells in 
each subsequent passage. The most likely explanation for the disintegration is residual accutase 
and DNAse solution within the cell suspension, which could not be completely removed during 
passages due to small volumes of cell suspension. Accutase contains collagenolytic enzymes likely 
to break down DuraGenTM made predominantly of collagen. 
Figure 4.3: DuraGen
TM 
disintegrates 24 hours after seeding with single transfected cells. Intact 
DuraGen
TM
 sample immediately after single cells were added (a). Fragments of DuraGen
TM
 (arrows) 
seen 24 hours after single cell seeding.  
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To remove the extra dissociation step identified as the cause of the disintegration, the alternative 
propagation format for NSCs was used, namely neurospheres. DuraGenTM seeding with 
neurospheres was trialled. Transfected neurospheres were seeded into DuraGenTM sheets and 
immediate visualisation under light microscopy was inconclusive in determining whether there was 
infiltration of the matrix. Seeding DuraGenTM with NSCs in the neurosphere format had not been 
tested until this stage so it was unknown whether the large balls of NSCs (average size: 100-200µm 
(232)) would be able to penetrate the pores (size: 25.9 ± 14.3µm) and adhere to the matrix. After 
24 hours, nuclear staining revealed neurospheres adherent to the matrix (figure 4.4)  
Figure 4.4: DuraGen
TM
 permits neurosphere attachment.  NSCs 24 hours after seeding as 
neurospheres in to DuraGen
TM 
matrix.  Scale bar = 200μm. 
At 24 hours after seeding into DuraGenTM and 48 hours after transfection, GFP expression was 
observed in NSCs within the DuraGenTM matrix (figure 4.5). A high proportion of neurospheres 
demonstrated at least one NSC with GFP expression, detected by anti-GFP antibody, within 
DuraGenTM (82.0 ± 3.55%) (n=4). Approximately 7-10% of the NSCs were transfected, this is an 
estimate due to the reasons described in section 2.8.6. On visualisation, transfected cells were 
evenly distributed and displayed normal morphologies with normal, rounded nuclei. No transfected 
cells were detected in any of the control samples.  
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Figure 4.5: Transfected NSCs growing within DuraGenTM matrix. 82.0 ± 3.55% of neurospheres had 
at least one NSC expressing GFP within DuraGenTM matrix 48 hours post transfection/ 24 hours post 
seeding into DuraGenTM (n=4) (video 4.1 in supplementary materials). Representative fluorescent 
images (a-e) taken from the same field (a) nuclei of NSCs forming two neurospheres (arrows) (b) 
GFP expression (c) anti-GFP antibody (aGFP) detects GFP expression. (d) Double merged image 
116 
 
displaying GFP expression detectability increased by anti-GFP. Arrows indicate NSCs expressing GFP 
(green) and anti-GFP (red). (e) Triple merged image demonstrates the proportion of GFP expression 
in NSCs within the DuraGenTM matrix.  Scale bar = 50μm. 
4.3.6 Genetic engineering and DuraGenTM construct formation did not negatively impact upon key 
safety parameters 
The following safety assays were performed to establish if transfection and DuraGenTM loading 
impacted upon the properties of NSCs.  
4.3.6.1 NSC viability unaffected by transfection and DuraGenTM loading 
After 24 hours in DuraGenTM, the transfected NSC population demonstrated high viability 
equivalent to that of the control. A high proportion of transfected NSCs were viable at 24 hours 
(92.8 ± 2.09%). There was no statistically detectable difference when compared to the control (p-
value = 0.392, two sample T-test, n=4) (figure 4.6c). Furthermore, there was a low proportion of 
pyknotic nuclei in the transfected NSCs (5.76  1.55%) which demonstrated no difference versus 
the control (p-value = 0.296, two sample T-test, n=4) (figure 4.6d). Visually, there was no detectable 
difference in the distribution of live and dead cells or pyknotic nuclei. The dead cells were evenly 
spaced throughout the matrix and no area preferentially exhibited dead cells. This indicates 
sufficient diffusion of nutrients throughout the 3D matrix. 
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Figure 4.6: Cell viability unaffected by pre-transfection and cell loading. Representative 
fluorescence images (a-b) of transfected NSCs (a) and control NSCs (b) in DuraGenTM at 48 hours 
post transfection/ 24 hours post-seeding in to DuraGenTM. Scale bar = 25µm. Bar graph (c) displaying 
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the high cell viability in both transfected NSC and control NSC populations growing in DuraGenTM 
(92.8  2.09% and 95.7  2.18% of the transfected NSC population and the control NSC population 
were live respectively) (p>0.05, two sample T-test, n=4). Bar graph (d) displaying low proportion of 
pyknotic nuclei in both transfected NSC and control NSC populations in DuraGenTM (5.76  1.55% 
and 3.51  1.15% of the transfected NSC and control NSC nuclei were pyknotic respectively) (p>0.05, 
two sample T-test, n=4). (e) Representative fluorescence image of a pyknotic nucleus (arrow) 
surrounded by normal nuclei. Scale bar = 25µm.  
4.3.6.2 Transfected cell populations expressed as NSC markers 
Transfection and cell loading did not impact the phenotype of the cells growing in DuraGenTM. At 
24 hours post seeding into DuraGenTM and 48 hours post transfection, the majority of cells were 
positive for NSC marker expression (93.9  0.35%) (figure 4.7a). Proportions of cells expressing 
nestin in the transfected population did not differ from that in the control population (p-value = 
0.304, two sample T-test, n=4) (figure 4.7c). The majority of nuclei also stained positive for NSC 
transcription factor expression (Sox-2). 96.7  0.492% of the transfected NSC population and 97.3 
 0.414% of the control NSC population were positive for Sox-2. This was not statistically different 
(p>0.05, two sample T-test, n=3).  In the transfected and control groups, no difference was 
visualised in the NSC morphology or patterns of NSC marker staining (figure 4.7a-b). >95% of GFP-
expressing cells at 48 hours post transfection were NSCs evidenced by the association of GFP-
expression and NSC marker staining. 
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Figure 4.7: Cells maintain NSC phenotype after transfection. Representative fluorescence images 
(a-b) of transfected NSCs (white arrows) (a) and control NSCs (b) expressing nestin in DuraGenTM at 
48 hours post transfection/ 24 hours post-seeding in to DuraGenTM. Scale bar = 25µm. 
Representative fluorescence images (c-d) of transfected NSCs (c) and control NSCs (d) expressing 
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sox-2 in DuraGenTM at 48 hours post transfection/ 24 hours post-seeding in to DuraGenTM. Scale bar 
= 25µm. Bar graph (e) displaying the proportions of nuclei associated with nestin in both transfected 
NSC and control NSC populations growing in DuraGenTM (93.9  0.35% and 92.9  0.69% of the 
transfected NSC population and the control NSC population were positive for nestin respectively) 
(p>0.05, two sample T-test, n=4). Bar graph (f) demonstrates the proportions of nuclei positive for 
Sox-2 (96.7  0.492% and 97.3  0.414% of the transfected NSC population and the control NSC 
population were positive for Sox-2 respectively) (p>0.05, two sample T-test, n=3).  
4.3.6.3 Proliferation of NSCs unaffected by transfection and loading into DuraGenTM 
Transfection and subsequent loading into DuraGenTM did not impact on the NSC’s ability to 
proliferate. At 24 hours in DuraGenTM and 48 hours post transfection, 58.7  3.43% of NSCs in the 
transfected population were EdU labelled versus 66.4  3.06% of the control NSC population (figure 
4.8). This was not statistically significant (p-value > 0.05, two sample T-test, n=4). 
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Figure 4.8: Cell proliferation unaffected by pre-transfection and cell loading. Representative 
fluorescence images (a-b) of transfected NSCs (white arrows) (a) and control NSCs (b) in DuraGen
TM
 
at 48 hours post transfection/ 24 hours post-seeding in to DuraGen
TM
.  (c) Bar graph displaying the 
proliferation rates in both transfected NSC and control NSC populations growing in DuraGen
TM 
(58.7 
 3.43% and 66.4  3.06% of the transfected NSC population and the control NSC population 
proliferated respectively) (p-value > 0.05, two sample T-test, n=4). Scale bar = 25μm.  
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4.3.6.4 Transfected NSC populations show expected differentiation profiles in DuraGenTM 
NSC differentiation was not influenced by transfection. At nine days post transfection (eight days 
post seeding into DuraGenTM/seven days after differentiation induction), all three differentiated cell 
types were present in the matrix (figure 4.9a-c). There were no differences in the proportions of 
each cell type when the transfected population were compared to the control population (p-values 
= 0.874, 0.883, 0.826 for astroglial lineage cells, neurons and oligodendrocytes respectively, two 
sample T-tests, n=4) (figure 4.9d).  
NSCs differentiated predominantly into astroglial lineage cells (66.7 ± 8.76%) which displayed 
normal morphological features (figure 4.9a). All GFP positive cells co-expressed GFAP. There was 
no evidence of GFP expression in either neurons or oligodendrocytes. Neurons, which contributed 
the second largest proportion (11.0 ± 4.85%), displayed normal cell bodies with extension of axons 
into the matrix (figure 4.9b). The smallest proportion of cells were oligodendrocytes (0.830 ± 
0.446%) which demonstrated their normal, highly processed morphology (figure 4.9c). The 
remaining proportion of cells are likely to be undifferentiated NSCs. Both neurons and 
oligodendrocytes were found in close spatial association with GFP-expressing cells assumed to be 
astroglial lineage cells (white arrows in figure 4.9b-c). GFP-expression in DuraGenTM was noted up 
to day nine post transfection when the experiments were terminated.  
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Figure 4.9: NSC differentiate into three types of daughter cells and astroglial lineage cells continue 
to express GFP. Representative fluorescence images (a-c) of differentiated transfected NSCs: 
astroglial lineage cells (a), neurons (b) and oligodendrocytes (c) display normal morphologies in the 
presence of transfected astroglial lineage cells (arrows) in DuraGenTM at nine days post transfection/ 
eight days post-seeding in to DuraGenTM. Scale bar = 25μm. Bar graph (d) demonstrates relative 
proportions of each cell type in transfected and control populations. Proportions of each cell type 
do not differ when transfected (p-values > 0.05, two sample T-tests, n=4). 
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4.4 Discussion 
4.4.1 Successful production of genetically engineered NSC-DuraGenTM construct 
To the best of our knowledge, this is the first time a population of genetically engineered NSCs have 
been incorporated within a neurosurgical grade material. This chapter has demonstrated a 
successful method of producing genetically engineered NSCs within DuraGenTM. The production of 
this construct did not reveal a negative impact of the biomaterial on the properties of the NSCs, 
indicating its safety.  
4.4.2 Overall vision for the clinical application of the ‘superconstruct’ 
The construct we have developed offers several potential benefits for the treatment for SCI. This 
pre-approved surgical material combined with the clinical benefits of magnetofection and 
minicircle technology offers a novel combinatorial therapy. Here, we used a GFP reporter protein 
to represent the potential to engineer NSCs with a therapeutic biomolecule. There are many 
proteins that could be expressed by this population of NSCs. BDNF would be a likely choice for a 
clinical therapy. It has the potential to improve neuronal survival and axonal growth, essential for 
regeneration in SCI (190). To engineer the NSCs using magnetofection and minicircle technology to 
express BDNF before DuraGenTM loading is likely to be possible as Fernandes and Chari have 
successfully magnetofected NSCs to express BDNF utilising DNA minicircles without negative 
implications to the NSC population (195). 
4.4.3 Transfection efficiency within DuraGenTM 
The transfection efficiency of the neurospheres loaded into DuraGenTM proved difficult to establish 
due to the nature of the neurosphere format (section 2.8.6). The estimate given appears 
comparable to that of neurospheres transfected in previous studies utilising magnetofection 
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technology (233). The efficiency of transfection of NSCs within a neurosphere format is lower than 
that of a monolayer NSC culture and of other cell types (table 4.1). This has been demonstrated 
before (233).  
Cell type Magnetic field Transfection efficiency Ref 
Neurospheres (NSCs) F=4Hz 9.91% (233) 
Monolayer (NSCs) F=4Hz 32.2% (223) 
Astrocytes F=1Hz 54% (211) 
OECs F=0Hz 57.7% (192) 
Table 4.1: Transfection efficiencies for neural transplant cells utilising magnetofection technology. 
Viral vector transfection of neurospheres would likely yield a higher transfection efficiency for 
transplantable cells in DuraGenTM. However, the use of viral vectors does not offer the clinical 
translation benefits of non-viral techniques such as magnetofection. With this in mind, a low level 
of therapeutic biomolecule release into the site of SCI might prove to be a safer therapy.  If a small 
proportion of NSCs produce the therapeutic biomolecule, the overall concentration of the protein 
is likely to be lower. This would prevent a high level of sustained growth factor release and the risks 
associated with high growth factor release including malignant transformation (234). 
Differentiated NSCs within DuraGenTM that maintained GFP-expression were positive for an 
astrocytic marker. In all experiments, transfected neurons or oligodendrocytes were never seen. 
This is in line with other studies utilising transfected NSCs, who found a high proportion of the 
differentiated cells to be astrocytes. Hughes et al used viral vectors to transfect neurospheres and 
after differentiation induction 96.6% of GFP-expressing cells were also GFAP positive (235).  
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Moreover, previous studies investigating magnetofection also demonstrated no GFP-expressing 
neurons or oligodendrocytes when transfected as neurospheres (223). Monolayer NSC transfection 
yielded mostly GFP-expressing astrocytes with less than ca 1% of the GFP-expressing cells co-
expressing TUJ1 (212).  
4.4.4 Failure of in-situ engineering method 
The ‘in situ engineering’ protocol did not produce a useful level of transfection. This method would 
have been beneficial for clinical translation as it provided a simple method of production. In 
addition, it would have allowed control over the peak expression of therapeutic biomolecules. 
Studies have demonstrated a peak transfection efficiency of 48 hours with magnetofection 
protocols (212). To maximise the concentration of therapeutic biomolecules released into the site 
of the injury, rapid production and implantation into SCI site would be required. 
The reason for the failure of this method remains unknown. Low transfection efficiency in collagen 
has been demonstrated before (141). Some potential reasons for the failure are outlined here. One 
hypothesis is that when the cells adhere to the matrix their behaviour changes and the cells may 
be less endocytotically active. Endocytosis is required for the MNP-DNA complexes to enter into 
the cells for transfection. Adams et al found that the cell membranes of NSCs growing on collagen 
substrates were ‘less active’ than those of cells growing on glass. They used field emission SEM to 
detect measures of membrane activity such as membrane ruffling, pitting, filopodia and nanopodia 
(141). 
The stiffness of a biomaterial substrate has been suggested as a reason for a decrease in 
endocytosis. The softer the substrate the less endocytotic activity occurs (236). The stiffness of 
DuraGenTM is currently unknown but it would be reasonable to assume that it is softer than 
standard in vitro culture substrates such as glass. 
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In addition, physical reasons were considered as to why the rate of transfection was negligible in 
DuraGenTM. There is a possibility that the MNPs may have adhered to the fibrous structure of 
DuraGenTM or been unable to circulate within it. This would have prevented the MNP-DNA 
complexes coming into contact with the cells for successful transfection.  
4.4.5 Why neurosphere loading is beneficial over single cell seeding in DuraGenTM  
After multiple optimisation steps, the resultant method for construct production was transfection 
as neurospheres and loading as neurospheres. This method removes the dissociation step involved 
with seeding single cells into DuraGenTM. Simplifying the process will assist at the point of clinical 
scale up and reduce the risk of enzymatic breakdown of the matrix, as seen in the pilot study of this 
chapter. In addition to these practical benefits, neurospheres represent a desirable format for cell 
transplantation. They have been shown to improve NSC survival at transplantation (20% less cell 
death compared to dissociated NSC transplants) and they improve long-term survival. At two weeks 
there was a three and a half fold improvement in NSC survival in the neurosphere transplant 
population (62). The option to seed DuraGenTM with neurospheres as opposed to single cells adds 
an extra element of protection for the NSCs.  
4.4.6 Possible use for magnetic resonance imaging (MRI) tracking  
It is beneficial to have the ability to track cell transplants. Clinicians could ensure cells have reached 
and remained at their target site with the assistance of cell tracking. Moreover, if cells migrated 
from the site they could be tracked and off target effects, such as tumours, could be diagnosed 
quickly and treated. The ability to label transplanted cells for in vivo tracking is vital for clinical 
translation. Weinberg et al demonstrated that the use of a clinical grade nanoparticle could be 
utilised to non-invasively track transplanted cells using MRI (237). Additionally, Tickle et al has 
demonstrated MRI detection of nanoparticle-labelled astrocytes within polymer matrices designed 
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for cell transplant (238). Although the MNPs utilised in this study are not compatible with MRI, the 
potential to utilise compatible nanoparticles would offer increasing benefits of this 
‘superconstruct’.  
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Chapter 5: Conclusions and future directions 
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5.1 Summary of key thesis findings 
This series of experiments has proven the utility of DuraGenTM, a neurosurgical grade biomaterial 
scaffold, as a NSC encapsulation device for the first time. We have demonstrated that DuraGenTM 
does not negatively impact on a population of NSCs, which demonstrated high viability, 
maintenance of their phenotype, proliferative capacity and the ability to differentiate. 
Combinatorial neuroregenerative therapies involving the delivery of stem cells have a significant 
need for protective biomaterial scaffolds. These findings demonstrate the potential utility of a 
neurosurgical grade material. To progress cellular therapy to the treatment of SCI, barriers to 
clinical translation must be overcome. This neurosurgical material offers the benefit of FDA-
approval to accelerate this process. 
We have also demonstrated the ability to formulate a ‘superconstruct’ where the regenerative 
benefits of a genetically engineered NSC population were combined with the clinical translatable 
benefits of DuraGenTM. The development of complex, combinatorial therapies demonstrates a key 
strategy for the treatment of neurological disease. Here we have developed a highly advanced 
construct with potential benefits for clinical translation that does not negatively impact upon the 
innate properties of the transplant cell population used.  
Overall, the proven use of this surgical grade material introduces the concept that many existing, 
pre-approved medical products may be amenable to multiple functions for a variety of tissue 
engineering challenges. 
5.2 The future direction for this research 
The proof of concept experiments described here unlock multiple new research directions. Firstly, 
the next steps to these experiments should be further investigation into the impact of DuraGenTM 
on NSCs using more advanced methods. For instance, functional assessment of the neurons within 
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the construct utilising electrophysiological measures would allow a more detailed assessment of 
DuraGenTM’s impact on cellular function. To further the concept of a pre-differentiated neural 
circuit within DuraGenTM, an investigation into the cell-cell interactions within the culture would be 
important. SEM of the construct could reveal whether astroglial lineage cells are guiding neuronal 
growth or whether oligodendrocytes are myelinating axons. 
It is important to recognise the significant impact physical properties of scaffolds, such as stiffness, 
has on the fate of cell transplant populations within the material. It would be beneficial to utilise 
elastography techniques to measure the stiffness of DuraGenTM. This could then be compared to 
the native stiffness of the brain and spinal cord and other commonly used biomaterial scaffolds. 
Other physical properties important for cell encapsulation include the material’s degradation rate. 
Integra Lifesciences report a degradation rate, when used for duraplasty, of two months (142). This 
rate could be affected by the presence of NSCs, therefore it would be useful to test the material’s 
degradation rate whilst encapsulating cells. Here, we tested DuraGenTM up to 16 days only.  
The inevitable next stage in testing the ‘superconstruct’ is to test its therapeutic benefit within 
experimental models of SCI. Organotypic slice culture offers the unique benefit of allowing 
visualisation of pathological and regenerative processes using a simple and tractable in vitro model 
system. Such testing could be carried out in rodent organotypic slice culture with rodent NSCs (15). 
Alternatively, our laboratory group have developed a method of culturing human organotypic slice 
models of neurological injury which could serve as a more representative model for DuraGenTM 
construct testing. Beyond in vitro investigations, the construct must be tested in vivo to elucidate 
whether it truly can promote spinal cord regeneration, including with behavioural testing to 
evaluate functional neurological recovery. During in vivo testing, it would be interesting to elucidate 
the cell release process from DuraGenTM. It appears, from the suggested ideal properties of a 
biomaterial scaffold, that the scaffold should maintain the cells until they begin to form a structure 
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representative of neural tissue and at this point the scaffold would degrade (105). Another point of 
note is whether this minimally immunogenic material will protect the transplant cells from immune 
attack. This could be investigated by adding NSCs within DuraGenTM to a culture of microglia and 
observing the response. Furthermore, testing the immune response in vivo would provide a more 
representative outcome. 
Controlling the direction of axonal growth presents a significant challenge for this cellular scaffold, 
as the growth of neurons was random within the material. There are multiple ways in which this 
could be overcome. In line with the work carried out by Bonner et al, a neurotrophin gradient could 
be manipulated in combination with the implantation of a DuraGenTM construct to encourage 
rostral and caudal axonal growth (230). This concept could be employed in one of two ways. Firstly, 
it could be used in vivo as intended. After a specified time, post implantation of the DuraGenTM-NSC 
construct, neurotrophic factors could be injected rostrally and caudally via intraspinal injection. In 
theory, this would encourage directional growth of neurons from within the construct to connect 
with the lesion edges. The alternative option is to utilise the neurotrophin gradient to pre-align 
neurons within the construct prior to implantation. To do this the DuraGenTM could be secured in a 
position within a petri dish. Two inner chambers within the dish, separated by a semi-permeable 
membrane, at each pole would contain neurotrophic factors. This gradient would encourage 
neurons, differentiated from NSCs, to grow in the direction of the neurotrophin pools (figure 5.1). 
Once sufficient time for alignment had passed the construct could then be implanted in that 
alignment into the site of SCI. This removes the need to inject into healthy cord as was required in 
the previous method. 
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Figure 5.1: Schematic representation of utilising a neurotrophin gradient to encourage linear axonal 
growth within DuraGenTM. 
Other methods to achieve axonal alignment may exist. Axial tension has been demonstrated to 
encourage axonal elongation and growth (239). The nature of DuraGenTM makes it amenable to 
stretch. If NSCs could be grown and differentiated on samples of DuraGenTM that were under 
tension it could, in theory, align the axonal fibres. This construct could then be subsequently 
implanted, in the correct orientation, in to a lesion site.   
Success has been demonstrated utilising electrical stimulation across the SCI lesion which improved 
function (40). I propose that the addition of this technology to the current approach of cellular 
transplantation within a biomaterial scaffold could increase regeneration. Harkema et al 
hypothesised that the epidural stimulation encouraged axonal regrowth. Combining electrical 
stimulation with a cell rich biomaterial scaffold, may target a sufficient number of the goals of 
regenerative therapy in a highly complex combinatorial therapy. 
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We investigated DuraGenTM as a matrix to encapsulate NSCs. However, as described in table 1.1 
many neural transplant cell types have been tested for neurological applications. Each cell type 
offers individual benefits. I envisage that if DuraGenTM can support NSCs and their daughter cells, it 
can support a population of astrocytes, OECs, OPCs or Schwann cells. DuraGenTM could then be 
personalised to each individual condition. For example, in multiple sclerosis there is a loss of 
oligodendrocytes and OPCs leading to failed attempts at remyelination (240), so a DuraGenTM 
construct seeded with a population of OPCs or mature oligodendrocytes could potentially be 
investigated to target the largest lesions for remyelination. Moreover, a dopaminergic neuron 
culture within DuraGenTM has the potential for use as a cell replacement therapy in cases of severe 
Parkinson’s disease. Complex mixed cultures of astrocytes, neurons and oligodendrocytes could 
replace lost tissue after tumour removal or traumatic brain injury. 
Finally, and most importantly, the use of DuraGenTM here has uncovered the potential for pre-
approved surgical materials to offer more than their current functions. In the introduction, several 
surgical materials were discussed for use as cell encapsulation devices. The next direction this 
research should be taken in is to investigate more of the available surgical materials for use as cell 
encapsulation devices, specifically fibrin glues, FlosealTM and SurgicelTM. Many more materials exist 
beyond those described. One I wish to draw particular attention to is VivostatTM. This is an 
autologous fibrin sealant used for haemostasis and dural sealing in neurosurgery. The use of a 
patient’s own blood to produce the sealant offers the benefit of immune rejection avoidance. If this 
biomaterial could be used to encapsulate cells for delivery it may also assist the transplanted cells 
in immune evasion. The potential for these pre-approved surgical materials can therefore be 
predicted to be far reaching. With the growing expense and delay in translating therapies to the 
clinic, it is vital that researchers capitalise on the resources and materials already available and 
routinely used in clinical practice.  
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Supplementary materials 
Find attached CD-ROM with the following files: 
Video 3.1: NSCs growing in 3D within DuraGenTM at 48 hours. Scale bar = 50 µm. 
Video 4.1: Transfected neurospheres within DuraGenTM matrix, 48 hours post transfection (24 
hours after DuraGenTM loading). Scale bar = 50 µm. 
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